Hydrochlorothiazide

also known as HCTZ · HCT · Dichlozid · Diazide · Dichlozid Tab · H12.5 · HCT G.L · HTC · +5 more

Developed for: hypertensive disorder · essential hypertension · cardiovascular disorder · type 2 diabetes mellitus · chronic kidney disease · diabetes mellitus · congestive heart failure · heart failure
+34 more
· cerebrovascular disorder · diabetic kidney disease · heart disorder · metabolic syndrome X · nephrolithiasis · photosensitivity disease · stroke disorder · urolithiasis · abdominal obesity-metabolic syndrome · atherosclerosis · coronary microvascular disorder · Dent disease · early onset hypertension · glucose metabolism disease · hyperlipidemia, combined, 2 · hypertensive heart disease · impaired renal function disease · obstructive sleep apnea syndrome · peripheral arterial disease · prediabetes syndrome · preeclampsia · proteinuria · resistant hypertension · atrial fibrillation · autosomal dominant hypocalcemia · autosomal dominant polycystic kidney disease · endolymphatic hydrops · eustachian tube disorder · idiopathic hypercalciuria · intracerebral hemorrhage · nephrolithiasis, calcium oxalate · optic neuritis · secondary hyperparathyroidism of renal origin · vascular disorder
Investigated by: Novartis · Boehringer Ingelheim · Daiichi Sankyo · Organon and Co · Novartis Pharmaceuticals · Mylan Pharmaceuticals Inc
+176 more
· Sanofi · Boryung Pharmaceutical Co., Ltd · AstraZeneca · Damanhour University · GlaxoSmithKline · Imperial College London · UMC Utrecht · Bristol-Myers Squibb · Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company · Merck Sharp & Dohme LLC · Seoul National University Hospital · Takeda · Tehran University of Medical Sciences · Teva Pharmaceuticals USA · University of Birmingham · Yonsei University · Canadian Institutes of Health Research (CIHR) · IlDong Pharmaceutical Co Ltd · Imperial College Healthcare NHS Trust · Medical University of Vienna · Northern California Institute of Research and Education · Pfizer · Radboud University Medical Center · Royal College of Surgeons, Ireland · Sankyo Pharma Gmbh · Seoul National University Bundang Hospital · Shanghai Jiao Tong University School of Medicine · Sir Mortimer B. Davis - Jewish General Hospital · The University of Texas Health Science Center, Houston · University of California, San Diego · University of Cambridge · University of Florida · University of Kansas Medical Center · VA Office of Research and Development · Vanderbilt University · Wake Forest University Health Sciences · Abbott · Academic Medical Center - University of Amsterdam · Ajou University · Anna Posadzy-Małaczyńska · Aragon Health Research Institute (IISAragon) · Asan Medical Center · Assistance Publique - Hôpitaux de Paris · Association for the Promotion of Research in Atherosclerosis, Thrombosis and Vascular Biology · Azidus Brasil · Baker Heart and Diabetes Institute · Barts & The London NHS Trust · Biomedis International Ltd. · British Heart Foundation · CH Annecy Genevois · CH Issoire · CH Moulins-Yzeure · CH Puy en Velay · CH Riom · Cadila Pharnmaceuticals · Capital Medical University · Caribbean College of Family Physicians · Central Hospital, Nancy, France · Centro Neurológico de Pesquisa e Reabiitação, Brazil · Cheil General Hospital and Women's Healthcare Center · Chiang Mai University · Chonbuk National University Hospital · Chong-Jin Kim · Chonnam National University Hospital · Columbia University · Cornell University · Corporacion Parc Tauli · Creighton University · Daiichi Sankyo Korea Co., Ltd. · Danish Cardiovascular Research Academy · Danish Heart Foundation · Dialysis Clinic, Inc. · DongGuk University · Dr. Reddy's Laboratories Limited · all 182 on the full record

Regulatory milestones approvals, filings & regulatory actions · 3 recorded

Milestone	Jurisdiction	Brand	Indication	Date	Sentence it was read from
Approved	EU (EMA)	CoAprovel	—	1998-10-14	europa.eu ↗
Label expansion	US (FDA)	HYDRODIURIL	—	1992-10-28	fda.gov ↗
Approved	US (FDA)	ESIDRIX	—	1959-02-12	fda.gov ↗

Trials 236 · started per year

today

US approved 1959

EU approved 1998

195819591960196119621963196419651966196719681969197019711972197319741975197619771978197919801981198219831984198519861987198819891990199119921993199419951996199719981999200020012002200320042005200620072008200920102011201220132014201520162017201820192020202120222023202420252026202720282029

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 04 trials
Phase 0	NCT04676399	Feb 2022 → Dec 2026 expected	chronic pain syndrome, hypertensive disorder	University of Kansas Medical Center	Active not recruiting	No outcome recorded
Phase 0	NCT03147092	Feb 2018 → Jun 2020	hypertensive disorder	Centro Neurológico de Pesquisa e Reabiitação, Brazil	Unknown	No outcome recorded
Phase 0	NCT02744456	Aug 2014 → Aug 2017	hypertensive disorder	Columbia University	Completed	No outcome recorded
Phase 0	NCT00649324	Oct 2005	—	Mylan Pharmaceuticals Inc	Completed	No outcome recorded
Phase 132 trials
Phase 1	NCT07544888	Nov 2025 → Mar 2026	heart disorder, hypertensive disorder	Shaikh Zayed Hospital, Lahore	Completed	No outcome recorded
Phase 1	NCT04934228	Jul 2021 → Aug 2026 overdue	diabetes mellitus, hypertensive disorder, obesity disorder	University of Kansas Medical Center	Recruiting	No outcome recorded
Phase 1	NCT04654312	Jan → Jul 2021	photosensitivity disease	Saarland University	Completed	No outcome recorded
Phase 1	NCT06083116	Aug → Oct 2019	type 2 diabetes mellitus	Jiangsu HengRui Medicine Co., Ltd.	Completed	No outcome recorded
Phase 1	NCT04197622	Mar 2019	—	Parc de Salut Mar	Completed	No outcome recorded
Phase 1	NCT03629067	Sep → Nov 2018	—	Boryung Pharmaceutical Co., Ltd	Completed	No outcome recorded
Phase 1	NCT03387657	Jan → Mar 2018	type 2 diabetes mellitus	Sanofi	Completed	No outcome recorded
Phase 1	NCT03390465	Dec 2017 → Jan 2018	—	Boryung Pharmaceutical Co., Ltd	Completed	No outcome recorded
Phase 1	NCT02183675	Jul → Oct 2014	—	Boehringer Ingelheim	Completed	No outcome recorded
Phase 1	NCT02094924	Apr → May 2014	hypertensive disorder	GlaxoSmithKline	Completed	No outcome recorded
Phase 1	NCT03889145	Dec 2013 → Feb 2014	—	IlDong Pharmaceutical Co Ltd	Completed	No outcome recorded
Phase 1	NCT01692717	Feb → May 2013	—	Azidus Brasil	Completed	No outcome recorded
Phase 1	NCT02962258	May → Jun 2011	—	Torrent Pharmaceuticals Limited	Completed	No outcome recorded
Phase 1	NCT01294631	Mar → Jul 2011	—	Johnson & Johnson Pharmaceutical Research & Development, L.L.C.	Completed	No outcome recorded
Phase 1	NCT01198249	Sep 2010 → Feb 2011	essential hypertension	Yonsei University	Completed	No outcome recorded
Phase 1	NCT00871871	Mar 2009 → Feb 2010	hypertensive disorder	Merck Sharp & Dohme LLC	Completed	No outcome recorded
Phase 1	NCT02276378	Jul → Aug 2008	—	Boehringer Ingelheim	Completed	No outcome recorded
Phase 1	NCT00671424	Mar → May 2008	type 2 diabetes mellitus	GlaxoSmithKline	Completed	No outcome recorded
Phase 1	NCT01020214	Nov 2006	—	Mylan Pharmaceuticals Inc	Completed	No outcome recorded
Phase 1	NCT01019590	Nov 2006	—	Mylan Pharmaceuticals Inc	Completed	No outcome recorded
Phase 1	NCT01149486	Jan → Feb 2004	—	Teva Pharmaceuticals USA	Completed	No outcome recorded
Phase 1	NCT02262780	Dec 2003 → Feb 2004	—	Boehringer Ingelheim	Completed	No outcome recorded
Phase 1	NCT00834067	Oct → Nov 2003	—	Teva Pharmaceuticals USA	Completed	No outcome recorded
Phase 1	NCT00835042	Oct → Nov 2003	—	Teva Pharmaceuticals USA	Completed	No outcome recorded
Phase 1	NCT00648011	Aug 2003	—	Mylan Pharmaceuticals Inc	Completed	No outcome recorded
Phase 1	NCT00649441	Aug → Sep 2003	—	Mylan Pharmaceuticals Inc	Completed	No outcome recorded
Phase 1	NCT02262572	Apr → Aug 2003	—	Boehringer Ingelheim	Completed	No outcome recorded
Phase 1	NCT00649233	Jan → Feb 2003	—	Mylan Pharmaceuticals Inc	Completed	No outcome recorded
Phase 1	NCT00649038	Dec 2002	—	Mylan Pharmaceuticals Inc	Completed	No outcome recorded
Phase 1	NCT00649597	Nov → Dec 2002	—	Mylan Pharmaceuticals Inc	Completed	No outcome recorded
Phase 1	NCT00223717	Jan 2001 → Jan 2017	hypertensive disorder	Vanderbilt University	Completed	No outcome recorded
Phase 1	NCT02176512	Sep → Oct 1998	—	Boehringer Ingelheim	Completed	No outcome recorded

Phase 213 trials
Phase 2	NCT07634068	Jun 2026 → Jun 2027 expected	cerebrovascular disorder	Huashan Hospital	Not yet recruiting	No outcome recorded
Phase 2	NCT05897372	Aug 2023 → Sep 2024	diabetic kidney disease	Iain Bressendorff	Terminated	No outcome recorded
Phase 2	NCT03329599	Feb 2019 → Dec 2021	atherosclerosis	Northern California Institute of Research and Education	Completed	No outcome recorded
Phase 2	NCT03024476	Sep 2016 → Dec 2017	hypertensive disorder, ischemic stroke	Seoul National University Bundang Hospital	Completed	No outcome recorded
Phase 2	NCT02278471	Dec 2015 → Jun 2018	hyperlipidemia, hypertensive disorder	Vanderbilt University	Completed	No outcome recorded
Phase 2	NCT02222480	Oct 2014 → May 2015	essential hypertension	Boryung Pharmaceutical Co., Ltd	Completed	No outcome recorded
Phase 2	NCT01480791	Jan 2012 → Dec 2013	diabetes mellitus, hypertensive disorder	Sir Mortimer B. Davis - Jewish General Hospital	Withdrawn	No outcome recorded
Phase 2	NCT01302899	Jan → Dec 2011	—	Novartis Pharmaceuticals	Terminated	No outcome recorded
Phase 2	NCT00567307	Jan → Dec 2009	cardiovascular disorder	Wake Forest University Health Sciences	Completed	No outcome recorded
Phase 2	NCT00388388	Mar 2007 → Dec 2009	hypertensive disorder, prediabetes syndrome	Sir Mortimer B. Davis - Jewish General Hospital	Terminated	No outcome recorded
Phase 2	NCT00603590	Nov 2006 → Jun 2008	heart disorder, hyperlipidemia, hypertensive disorder	Tehran University of Medical Sciences	Completed	No outcome recorded
Phase 2	NCT00374855	Sep → Nov 2006	hypertensive disorder	Eli Lilly and Company	Completed	No outcome recorded
Phase 2	NCT00153049	Jun 2004 → Jun 2005	essential hypertension	Boehringer Ingelheim	Completed	No outcome recorded

Phase 2/32 trials
Phase 2/3	NCT07469722	Mar 2026 → Jan 2028 expected	congestive heart failure	Hospital de Clinicas de Porto Alegre	Not yet recruiting	No outcome recorded
Phase 2/3	NCT00638482	Jul 2003 → Dec 2005	Dent disease, nephrolithiasis	Assistance Publique - Hôpitaux de Paris	Terminated	No outcome recorded
Phase 379 trials
Phase 3	NCT05963568	Apr 2026 → Jan 2029 expected	stroke disorder	Northern California Institute of Research and Education	Recruiting	No outcome recorded
Phase 3	NCT07008365	Mar 2025 → Nov 2026 expected	cardio-renal syndrome, congestive heart failure	Aragon Health Research Institute (IISAragon)	Recruiting	No outcome recorded
Phase 3	NCT04465123	Aug 2020 → Jul 2022	acute kidney injury, heart failure	Chiang Mai University	Unknown	No outcome recorded
Phase 3	NCT03057431	Mar 2017 → Dec 2021	nephrolithiasis	Insel Gruppe AG, University Hospital Bern	Completed	No outcome recorded
Phase 3	NCT03246555	Jul 2016 → Aug 2019	—	Boryung Pharmaceutical Co., Ltd	Completed	No outcome recorded
Phase 3	NCT03249285	Mar 2016 → Mar 2018	essential hypertension	Ospedale San Raffaele	Unknown	No outcome recorded
Phase 3	NCT03459560	Dec 2015 → Mar 2022	cardiovascular disorder	Tehran University of Medical Sciences	Unknown	No outcome recorded
Phase 3	NCT02738632	May 2015 → Aug 2016	essential hypertension	IlDong Pharmaceutical Co Ltd	Completed	No outcome recorded
Phase 3	NCT02277691	Nov 2014 → Apr 2016	essential hypertension	Takeda	Completed	No outcome recorded
Phase 3	NCT01975246	Nov 2013 → Jun 2014	essential hypertension	Boehringer Ingelheim	Completed	No outcome recorded
Phase 3	NCT01911780	Jul 2013 → Jan 2015	essential hypertension	Boehringer Ingelheim	Completed	No outcome recorded
Phase 3	NCT02466490	Apr 2013 → Feb 2014	essential hypertension	Stendhal Americas, S.A.	Completed	No outcome recorded
Phase 3	NCT01313702	Oct 2012 → Apr 2014	cardiovascular disorder	Hospital do Coracao	Withdrawn	No outcome recorded
Phase 3	NCT01646437	Jun 2012 → Jun 2020	cardiovascular disorder	Population Health Research Institute	Completed	No outcome recorded
Phase 3	NCT01245608	Oct 2011 → Jan 2018	cardiovascular disorder	Tehran University of Medical Sciences	Completed	No outcome recorded
Phase 3	NCT01307046	Mar 2011 → Feb 2012	essential hypertension	Organon and Co	Completed	No outcome recorded
Phase 3	NCT01326676	Feb 2011 → Jul 2012	cardiovascular disorder	Imperial College London	Withdrawn	No outcome recorded
Phase 3	NCT01302691	Jan 2011 → Apr 2012	hypertensive disorder	Merck Sharp & Dohme LLC	Completed	No outcome recorded
Phase 3	NCT01259297	Jan 2011 → Nov 2012	—	Novartis Pharmaceuticals	Terminated	No outcome recorded
Phase 3	NCT01258673	Nov 2010 → Dec 2011	essential hypertension	Boryung Pharmaceutical Co., Ltd	Completed	No outcome recorded
Phase 3	NCT01057537	Jun 2010 → Jul 2012	cardiovascular disorder	Imperial College London	Completed	No outcome recorded
Phase 3	NCT01113047	May → Oct 2010	essential hypertension	Novartis	Completed	No outcome recorded
Phase 3	NCT00923091	Jun 2009 → Jan 2011	essential hypertension	Daiichi Sankyo	Completed	No outcome recorded
Phase 3	NCT00902538	Apr 2009 → Sep 2010	essential hypertension	Daiichi Sankyo	Completed	No outcome recorded
Phase 3	NCT00818883	Feb → Nov 2009	essential hypertension	Takeda	Completed	No outcome recorded
Phase 3	NCT00765674	Sep 2008 → Aug 2009	hypertensive disorder	Novartis	Completed	No outcome recorded
Phase 3	NCT00667719	Jun 2008 → Oct 2009	essential hypertension	Novartis	Completed	No outcome recorded
Phase 3	NCT00705575	Jun 2008 → Apr 2009	essential hypertension	Novartis	Completed	No outcome recorded
Phase 3	NCT00548067	Sep 2007 → Mar 2008	hypertensive disorder	Novartis	Completed	No outcome recorded
Phase 3	NCT00441350	Jul 2007 → May 2008	hypertensive disorder	Menarini Group	Completed	No outcome recorded
Phase 3	NCT00523744	Jul → Dec 2007	hypertensive disorder	Novartis	Completed	No outcome recorded
Phase 3	NCT00447603	May → Oct 2007	hypertensive disorder	Organon and Co	Terminated	No outcome recorded
Phase 3	NCT00459056	Apr 2007 → May 2010	abdominal obesity-metabolic syndrome, hypertensive disorder	St. Paul Heart Clinic	Completed	No outcome recorded
Phase 3	NCT00430508	Feb 2007 → Mar 2008	essential hypertension	Daiichi Sankyo	Completed	No outcome recorded
Phase 3	NCT00430950	Feb 2007 → May 2008	essential hypertension	Daiichi Sankyo	Completed	No outcome recorded
Phase 3	NCT00434967	Jan 2007 → Jan 2008	hypertensive disorder	AstraZeneca	Completed	No outcome recorded
Phase 3	NCT00402103	Nov 2006 → Apr 2008	essential hypertension	Novartis	Completed	No outcome recorded
Phase 3	NCT00386607	Oct 2006 → Jul 2008	essential hypertension	Novartis	Completed	No outcome recorded
Phase 3	NCT00387517	Oct 2006 → Aug 2007	essential hypertension	Novartis	Completed	No outcome recorded
Phase 3	NCT00386139	Sep 2006 → Jul 2007	hypertensive disorder	Novartis	Completed	No outcome recorded
Phase 3	NCT00383929	Sep 2006 → Aug 2007	hypertensive disorder	AstraZeneca	Completed	No outcome recorded
Phase 3	NCT00872586	Aug 2006 → Jul 2007	essential hypertension	Daiichi Sankyo	Completed	No outcome recorded
Phase 3	NCT00355589	Jul 2006 → Mar 2007	essential hypertension	Pfizer	Completed	No outcome recorded
Phase 3	NCT00367094	Jul 2006 → ?	essential hypertension	Novartis	Completed	No outcome recorded
Phase 3	NCT00354991	Jun 2006 → Apr 2007	essential hypertension	Merck Sharp & Dohme LLC	Completed	No outcome recorded
Phase 3	NCT00326768	May 2006 → Aug 2007	essential hypertension	Boehringer Ingelheim	Completed	No outcome recorded
Phase 3	NCT00338936	May 2006 → Sep 2007	essential hypertension	Novartis	Completed	No outcome recorded
Phase 3	NCT00327587	May 2006 → Aug 2007	hypertensive disorder	Novartis	Completed	No outcome recorded
Phase 3	NCT00449111	Mar → Sep 2006	hypertensive disorder	Organon and Co	Terminated	No outcome recorded
Phase 3	NCT00311740	Mar → Sep 2006	hypertensive disorder	Novartis	Completed	No outcome recorded
Phase 3	NCT00289887	Feb 2006 → Feb 2007	hypertensive disorder	Organon and Co	Completed	No outcome recorded
Phase 3	NCT00267943	Jan 2006 → Jan 2007	hypertensive disorder	Boehringer Ingelheim	Completed	No outcome recorded
Phase 3	NCT00396656	Dec 2005 → Dec 2007	hypertensive disorder	Novartis	Completed	No outcome recorded
Phase 3	NCT00273299	Nov 2005 → Jul 2006	hypertensive disorder	Novartis	Completed	No outcome recorded
Phase 3	NCT00257491	Nov 2005 → Aug 2006	hypertensive disorder	Boehringer Ingelheim	Completed	No outcome recorded
Phase 3	NCT00250562	Oct 2005 → Jun 2006	hypertensive disorder	Novartis	Completed	No outcome recorded
Phase 3	NCT00239369	Oct 2005 → Aug 2006	hypertensive disorder	Boehringer Ingelheim	Completed	No outcome recorded
Phase 3	NCT00546052	Sep 2005 → Jan 2008	hypertensive disorder, metabolic disease	Organon and Co	Completed	No outcome recorded
Phase 3	NCT00400218	Sep 2005 → Jul 2006	essential hypertension	Organon and Co	Completed	No outcome recorded
Phase 3	NCT00139698	Sep 2005 → Jul 2006	essential hypertension	Pfizer	Completed	No outcome recorded
Phase 3	NCT00263003	Jun 2005 → ?	hypertensive disorder	Sanofi	Completed	No outcome recorded
Phase 3	NCT00146341	Apr 2005 → Sep 2006	hypertensive disorder	Boehringer Ingelheim	Completed	No outcome recorded
Phase 3	NCT00398541	Mar 2005 → Apr 2007	hypertensive disorder	Organon and Co	Completed	No outcome recorded
Phase 3	NCT00144222	Jan → Aug 2005	essential hypertension	Boehringer Ingelheim	Completed	No outcome recorded
Phase 3	NCT00307060	Dec 2004 → Jun 2005	hypertensive disorder	Organon and Co	Completed	No outcome recorded
Phase 3	NCT00171015	Dec 2004 → Apr 2005	hypertensive disorder	Novartis	Completed	No outcome recorded
Phase 3	NCT00095550	Oct 2004 → Jun 2005	hypertensive disorder	Bristol-Myers Squibb	Completed	No outcome recorded
Phase 3	NCT00170989	Sep 2004 → Jul 2005	hypertensive disorder	Novartis	Completed	No outcome recorded
Phase 3	NCT00095394	Sep 2004 → May 2005	hypertensive disorder	Bristol-Myers Squibb	Completed	No outcome recorded
Phase 3	NCT00241007	Dec 2003 → Mar 2005	hypertensive disorder	Novartis	Completed	No outcome recorded
Phase 3	NCT00642096	Jun 2003 → Jul 2004	essential hypertension	AstraZeneca	Completed	No outcome recorded
Phase 3	NCT00092209	Apr → Nov 2002	essential hypertension	Organon and Co	Completed	No outcome recorded
Phase 3	NCT00185172	Jan 2002 → Jun 2005	essential hypertension	Sankyo Pharma Gmbh	Completed	No outcome recorded
Phase 3	NCT02177500	Jan → May 2000	hypertensive disorder	Boehringer Ingelheim	Completed	No outcome recorded
Phase 3	NCT02177487	Jun 1999 → Jan 2000	hypertensive disorder	Boehringer Ingelheim	Completed	No outcome recorded
Phase 3	NCT02177435	Feb → Sep 1999	hypertensive disorder	Boehringer Ingelheim	Completed	No outcome recorded
Phase 3	NCT02177422	Jun 1998 → Nov 1999	hypertensive disorder	Boehringer Ingelheim	Completed	No outcome recorded
Phase 3	NCT00000525	Jul 1986 → Sep 1989	cardiac arrest, hypertensive disorder, sudden arrhythmia death syndrome	University of California, San Francisco	Completed	No outcome recorded
Phase 3	NCT02493322	? → Jun 2025	essential hypertension	EMS	Withdrawn	No outcome recorded

Phase 484 trials
Phase 4	NCT07593612	Jun 2026 → Jan 2027 expected	heart failure	Lucrecia Maria Burgos	Not yet recruiting	No outcome recorded
Phase 4	NCT05917275	Apr 2024 → Oct 2025	essential hypertension	Radboud University Medical Center	Unknown	No outcome recorded
Phase 4	NCT05443932	Mar → Dec 2024	urolithiasis	Medical University of Vienna	Unknown	No outcome recorded
Phase 4	NCT05171686	Feb 2023 → Oct 2025	chronic kidney disease, hypertensive disorder	VA Office of Research and Development	Completed	No outcome recorded
Phase 4	NCT05049616	Oct 2021 → Jun 2022	preeclampsia	The University of Texas Health Science Center, Houston	Completed	No outcome recorded
Phase 4	NCT03423355	Sep 2021 → Mar 2023	type 2 diabetes mellitus	University Hospital Tuebingen	Withdrawn	No outcome recorded
Phase 4	NCT04192110	Aug 2020	chronic kidney disease	VA Office of Research and Development	Withdrawn	No outcome recorded
Phase 4	NCT04330300	Apr 2020 → Jul 2021	COVID-19, essential hypertension	National University of Ireland, Galway, Ireland	Suspended	No outcome recorded
Phase 4	NCT04242758	Jun → Dec 2019	glucose metabolism disease, impaired renal function disease	University of Pisa	Unknown	No outcome recorded
Phase 4	NCT03978884	Jun 2019 → May 2020	diabetes mellitus, hypertensive disorder	The University of The West Indies	Withdrawn	No outcome recorded
Phase 4	NCT03892148	May 2019 → Jan 2023	heart failure	University Hospital, Clermont-Ferrand	Completed	No outcome recorded
Phase 4	NCT03682692	Jun 2018 → Jun 2021	hypertensive disorder	Shanghai Jiao Tong University School of Medicine	Completed	No outcome recorded
Phase 4	NCT03461003	Apr 2018 → Nov 2020	early onset hypertension	The University of Texas Health Science Center, Houston	Completed	No outcome recorded
Phase 4	NCT03254849	Dec 2017 → Apr 2020	type 2 diabetes mellitus	Profil Institute for Metabolic Research GmbH	Completed	No outcome recorded
Phase 4	NCT02742467	Jun 2017 → Jun 2018	hypertensive disorder	University of Abuja	Completed	No outcome recorded
Phase 4	NCT02646397	Feb 2016 → Dec 2017	chronic kidney disease	Shanghai Changzheng Hospital	Unknown	No outcome recorded
Phase 4	NCT02377661	Mar 2015 → May 2017	hypertensive disorder	Wilhelminenspital Vienna	Completed	No outcome recorded
Phase 4	NCT02710071	Jan 2015 → Apr 2016	essential hypertension	University of California, San Diego	Completed	No outcome recorded
Phase 4	NCT02699125	Jan 2015 → Jun 2016	obstructive sleep apnea syndrome	University of California, San Diego	Completed	No outcome recorded
Phase 4	NCT02294539	Aug 2014 → May 2016	hypertensive disorder	Chong-Jin Kim	Completed	No outcome recorded
Phase 4	NCT02217852	Aug 2014 → Jan 2016	hypertensive disorder	West China Hospital	Unknown	No outcome recorded
Phase 4	NCT02100462	Mar 2014 → Dec 2016	hypertensive disorder	Creighton University	Unknown	No outcome recorded
Phase 4	NCT01977430	Nov 2013 → Mar 2015	chronic kidney disease	Corporacion Parc Tauli	Unknown	No outcome recorded
Phase 4	NCT01198496	Oct 2010 → Dec 2017	essential hypertension, stroke disorder	Biomedis International Ltd.	Unknown	No outcome recorded
Phase 4	NCT01138423	Aug 2010 → Feb 2012	hypertensive disorder, metabolic syndrome X	UMC Utrecht	Completed	No outcome recorded
Phase 4	NCT01056731	Feb 2010 → Oct 2011	hypertensive disorder	Novartis	Completed	No outcome recorded
Phase 4	NCT00994617	Jan 2010 → Dec 2014	essential hypertension, resistant hypertension	University of Cambridge	Unknown	No outcome recorded
Phase 4	NCT01070030	Jan → Oct 2010	hypertensive disorder	Novartis	Completed	No outcome recorded
Phase 4	NCT02351973	Nov 2009 → Jul 2015	essential hypertension	University of Cambridge	Unknown	No outcome recorded
Phase 4	NCT00896389	Oct 2009 → Dec 2012	hypertensive disorder	University of Maryland, Baltimore	Completed	No outcome recorded
Phase 4	NCT01012479	Oct 2009 → May 2010	essential hypertension	Takeda	Completed	No outcome recorded
Phase 4	NCT00902304	Jul 2009 → Jul 2011	hypertensive disorder	Novartis Pharmaceuticals	Completed	No outcome recorded
Phase 4	NCT00931710	Jul 2009 → Jan 2010	hypertensive disorder	Novartis	Completed	No outcome recorded
Phase 4	NCT00942994	Jun 2009 → Mar 2010	hypertensive disorder	Novartis	Completed	No outcome recorded
Phase 4	NCT00926289	Jun 2009 → Apr 2010	hypertensive disorder	Boehringer Ingelheim	Completed	No outcome recorded
Phase 4	NCT01819220	Apr 2009 → Nov 2014	hypertensive disorder	Yonsei University	Completed	No outcome recorded
Phase 4	NCT00795847	Nov 2008 → Nov 2010	hypertensive disorder	Kurume University	Completed	No outcome recorded
Phase 4	NCT00797316	Nov 2008 → Dec 2009	hypertensive disorder	Novartis	Completed	No outcome recorded
Phase 4	NCT00791258	Nov 2008 → Aug 2009	hypertensive disorder	Daiichi Sankyo	Completed	No outcome recorded
Phase 4	NCT00787605	Nov 2008 → Jan 2010	diabetes mellitus, hypertensive disorder	Novartis	Completed	No outcome recorded
Phase 4	NCT00765947	Sep 2008 → Aug 2009	essential hypertension	Novartis	Completed	No outcome recorded
Phase 4	NCT00772577	Aug 2008 → Mar 2009	hypertensive disorder	Novartis	Completed	No outcome recorded
Phase 4	NCT00739596	Jul 2008 → Mar 2009	hypertensive disorder	Novartis Pharmaceuticals	Completed	No outcome recorded
Phase 4	NCT00654745	May 2008 → Apr 2009	essential hypertension, type 2 diabetes mellitus	Daiichi Sankyo	Completed	No outcome recorded
Phase 4	NCT00698646	Apr 2008 → Jun 2009	essential hypertension	Novartis Pharmaceuticals	Completed	No outcome recorded
Phase 4	NCT00670566	Apr 2008 → Mar 2009	hypertensive disorder	Sanofi	Completed	No outcome recorded
Phase 4	NCT00687206	Mar → May 2008	erectile dysfunction, hypertensive disorder	Federico II University	Completed	No outcome recorded
Phase 4	NCT00496834	Feb 2008 → Sep 2009	hypertensive disorder	Organon and Co	Completed	No outcome recorded
Phase 4	NCT00621153	Feb 2008 → Mar 2009	hypertensive disorder	AstraZeneca	Completed	No outcome recorded
Phase 4	NCT00492128	Sep 2007 → May 2009	hypertensive disorder	Yokohama City University Medical Center	Completed	No outcome recorded
Phase 4	NCT01431508	Aug 2007 → Jun 2009	essential hypertension	Organon and Co	Completed	No outcome recorded
Phase 4	NCT00457483	Aug 2007 → Dec 2010	essential hypertension	Radboud University Medical Center	Completed	No outcome recorded
Phase 4	NCT00439738	Dec 2006 → Nov 2007	hypertensive disorder	Novartis Pharmaceuticals	Completed	No outcome recorded
Phase 4	NCT00425997	Dec 2006 → Oct 2007	hypertensive disorder	Novartis	Completed	No outcome recorded
Phase 4	NCT00412932	Dec 2006 → Apr 2008	hypertensive disorder	Daiichi Sankyo	Completed	No outcome recorded
Phase 4	NCT00430638	Dec 2006 → Oct 2007	hypertensive disorder	Daiichi Sankyo	Completed	No outcome recorded
Phase 4	NCT01425411	Nov 2006 → Nov 2008	hypertensive disorder, hypertensive heart disease	Mustafa Kemal University	Completed	No outcome recorded
Phase 4	NCT00403481	Nov 2006 → Nov 2007	hypertensive disorder	Daiichi Sankyo	Completed	No outcome recorded
Phase 4	NCT00426478	Nov 2006 → Sep 2007	essential hypertension	Novartis	Completed	No outcome recorded
Phase 4	NCT00443612	Sep 2006 → Oct 2008	hypertensive disorder	Sanofi	Completed	No outcome recorded
Phase 4	NCT00400777	Aug 2006 → Nov 2007	hypertensive disorder	Novartis	Completed	No outcome recorded
Phase 4	NCT00890591	Aug 2006 → Jun 2007	essential hypertension	Daiichi Sankyo	Completed	No outcome recorded
Phase 4	NCT00607035	May 2006 → Apr 2008	hypertensive disorder	Jichi Medical University	Completed	No outcome recorded
Phase 4	NCT00311155	Mar 2006 → Apr 2008	essential hypertension	Sankyo Pharma Gmbh	Completed	No outcome recorded
Phase 4	NCT00335673	Feb → Nov 2006	hypertensive disorder	Sanofi	Completed	No outcome recorded
Phase 4	NCT00280540	Dec 2005 → Aug 2006	hypertensive disorder	Novartis	Completed	No outcome recorded
Phase 4	NCT00535925	Oct 2005 → Dec 2011	diabetic kidney disease	University of Campania Luigi Vanvitelli	Completed	No outcome recorded
Phase 4	NCT00246519	Oct 2005 → Dec 2010	hypertensive disorder	University of Florida	Completed	No outcome recorded
Phase 4	NCT00168779	Sep 2005 → Jul 2006	hypertensive disorder	Boehringer Ingelheim	Completed	No outcome recorded
Phase 4	NCT00185120	Sep 2005 → Sep 2006	hypertensive disorder	Daiichi Sankyo	Completed	No outcome recorded
Phase 4	NCT00821574	Jul 2005 → Mar 2007	hyperlipidemia, combined, 2	Novartis	Completed	No outcome recorded
Phase 4	NCT00157963	Feb 2005 → Feb 2006	essential hypertension	Organon and Co	Completed	No outcome recorded
Phase 4	NCT00170937	Nov 2004 → Mar 2006	hypertensive disorder, metabolic syndrome X	Novartis	Completed	No outcome recorded
Phase 4	NCT00185068	Mar → Oct 2004	hypertensive disorder	Daiichi Sankyo	Completed	No outcome recorded
Phase 4	NCT00171782	Feb → Dec 2004	hypertensive disorder	Novartis	Completed	No outcome recorded
Phase 4	NCT00154271	Jan 2004 → Jun 2005	hypertensive disorder	Novartis	Completed	No outcome recorded
Phase 4	NCT00847834	Dec 2003 → Jun 2004	essential hypertension	Sanofi	Completed	No outcome recorded
Phase 4	NCT00240448	Sep 2003 → Jun 2004	hypertensive disorder	Boehringer Ingelheim	Completed	No outcome recorded
Phase 4	NCT00171054	Sep 2003 → Oct 2007	hypertensive disorder	Novartis	Completed	No outcome recorded
Phase 4	NCT00171561	Mar 2003 → Sep 2006	hypertensive disorder	Novartis	Completed	No outcome recorded
Phase 4	NCT00306696	Oct 2002 → Jan 2004	diabetes mellitus	GlaxoSmithKline	Completed	No outcome recorded
Phase 4	NCT03921736	Jan 2000 → Mar 2001	essential hypertension	Anna Posadzy-Małaczyńska	Completed	No outcome recorded
Phase 4	NCT02172586	Jan 2000 → Jan 2002	hypertensive disorder	Boehringer Ingelheim	Completed	No outcome recorded
Phase 4	NCT00133692	Sep 1997 → Feb 2003	coronary artery disorder, hypertensive disorder	University of Florida	Completed	No outcome recorded

Phase not applicable22 trials
—	NCT06790927	Feb 2025 → Dec 2026 expected	hypertensive disorder	Shanghai Jiao Tong University School of Medicine	Not yet recruiting	No outcome recorded
—	NCT07020104	Jan 2025 → Dec 2039 expected	chronic kidney disease	Academic Medical Center - University of Amsterdam	Recruiting	No outcome recorded
—	NCT06491940	Aug 2024 → Jul 2025 overdue	proteinuria	RESnTEC, Institute of Research	Not yet recruiting	No outcome recorded
—	NCT06710600	Sep 2022 → Apr 2024	photosensitivity disease	Medical University of Vienna	Completed	No outcome recorded
—	NCT04182854	Oct 2019 → Feb 2020	antidepressant type abuse	Capital Medical University	Unknown	No outcome recorded
—	NCT02765009	Jun 2016 → Jul 2019	—	Central Hospital, Nancy, France	Completed	No outcome recorded
—	NCT02255253	Oct 2014 → Feb 2015	hypertensive disorder	The George Institute for Global Health, China	Completed	No outcome recorded
—	NCT02711670	Feb 2014 → Jun 2017	urolithiasis	VA New York Harbor Healthcare System	Completed	No outcome recorded
—	NCT04371874	Jan 2014 → Jul 2017	hypertensive disorder	First Affiliated Hospital Xi'an Jiaotong University	Completed	No outcome recorded
—	NCT01858610	Mar → Apr 2013	—	Damanhour University	Completed	No outcome recorded
—	NCT01858623	Feb → Mar 2013	—	Damanhour University	Completed	No outcome recorded
—	NCT01767298	Oct → Dec 2012	—	Damanhour University	Completed	No outcome recorded
—	NCT01658657	Oct 2012 → Jul 2014	hypertensive disorder, proteolytic capacity of plasma	University of North Carolina, Chapel Hill	Completed	No outcome recorded
—	NCT01767259	Oct → Dec 2012	—	Damanhour University	Completed	No outcome recorded
—	NCT01506505	Jul 2012 → Jul 2013	cerebrovascular disorder, peripheral arterial disease	UMC Utrecht	Completed	No outcome recorded
—	NCT00822107	Jan 2009 → Jan 2013	Gitelman syndrome	Oregon Health and Science University	Completed	No outcome recorded
—	NCT00700583	May → Jun 2008	—	Seoul National University Hospital	Completed	No outcome recorded
—	NCT00424801	Jan 2007 → Dec 2008	coronary microvascular disorder, essential hypertension	University of Aarhus	Terminated	No outcome recorded
—	NCT00834600	Dec 2005 → Oct 2011	hypertensive disorder	The Louis & Rachel Rudin Foundation	Completed	No outcome recorded
—	NCT00690521	Oct 2004 → Nov 2009	congestive heart failure	University of New Mexico	Completed	No outcome recorded
—	NCT00162474	Sep 2003 → Dec 2030 expected	—	Hadassah Medical Organization	Recruiting	No outcome recorded
—	NCT00247910	Oct 2001 → Jun 2006	hypertensive disorder	University of British Columbia	Completed	No outcome recorded

Also used as a comparator or background therapy in 169 trials

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 03 trials
Phase 0	NCT04423627 Comparator	Jun 2021 → Jul 2025	hypertensive disorder	University of Iowa	Completed	No outcome recorded
Phase 0	NCT01804777 Comparator	Mar 2013 → Dec 2014	hypertensive disorder, proteinuria, type 2 diabetes mellitus	University of New Mexico	Terminated	No outcome recorded
Phase 0	NCT00574834 Comparator	Mar 2007 → Aug 2014	metabolic syndrome X	University of Maryland, Baltimore	Terminated	No outcome recorded
Phase 111 trials
Phase 1	NCT06205407 Comparator	Dec 2023 → Mar 2024	—	Pfizer	Completed	No outcome recorded
Phase 1	NCT03971929 Comparator	Jul 2019 → Sep 2020	hypertensive disorder	Jiangsu HengRui Medicine Co., Ltd.	Completed	No outcome recorded
Phase 1	NCT03032315 Comparator	Oct → Dec 2016	—	IlDong Pharmaceutical Co Ltd	Completed	No outcome recorded
Phase 1	NCT02739672 Comparator	Jan → Apr 2016	—	IlDong Pharmaceutical Co Ltd	Completed	No outcome recorded
Phase 1	NCT01370655 Comparator	Jun → Dec 2011	hypertensive disorder	Merck Sharp & Dohme LLC	Completed	No outcome recorded
Phase 1	NCT01276288 Comparator	Jan → Jun 2011	type 2 diabetes mellitus	Boehringer Ingelheim	Completed	No outcome recorded
Phase 1	NCT01103245 Comparator	Mar 2010 → Jul 2012	diabetes mellitus	Vanderbilt University Medical Center	Completed	No outcome recorded
Phase 1	NCT00923533 Comparator	Mar → May 2009	essential hypertension	Boryung Pharmaceutical Co., Ltd	Completed	No outcome recorded
Phase 1	NCT01149473 Comparator	Mar → Apr 2004	—	Teva Pharmaceuticals USA	Completed	No outcome recorded
Phase 1	NCT00649688 Comparator	Jan → Feb 2003	—	Mylan Pharmaceuticals Inc	Completed	No outcome recorded
Phase 1	NCT02187523 Comparator	Oct → Dec 1999	—	Boehringer Ingelheim	Completed	No outcome recorded

Phase 1/21 trial
Phase 1/2	NCT03179163 Comparator	Jul 2016 → Aug 2022	essential hypertension	Penn State University	Terminated	No outcome recorded
Phase 213 trials
Phase 2	NCT06111885 Comparator	Oct 2024 → Jun 2027 expected	urolithiasis	Insel Gruppe AG, University Hospital Bern	Recruiting	No outcome recorded
Phase 2	NCT03658850 Comparator	Oct 2018 → Dec 2019	—	University of Sao Paulo	Unknown	No outcome recorded
Phase 2	NCT03295734 Comparator	May 2018 → Sep 2024	hypertensive disorder	University of Alabama at Birmingham	Completed	No outcome recorded
Phase 2	NCT03198793 Background	Oct 2017 → Oct 2018	essential hypertension	Quantum Genomics SA	Completed	No outcome recorded
Phase 2	NCT02824718 Comparator	Jun 2017 → May 2020	autosomal dominant hypocalcemia	Assistance Publique - Hôpitaux de Paris	Completed	No outcome recorded
Phase 2	NCT01879527 Comparator	Mar 2014 → Apr 2016	optic neuritis	Medical University of Vienna	Unknown	No outcome recorded
Phase 2	NCT01983462 Comparator	Oct 2013 → Jun 2020	hypertensive disorder, obesity disorder	Gary L. Pierce	Terminated	No outcome recorded
Phase 2	NCT01692301 Background	Dec 2012 → Apr 2015	hypertensive disorder	Novartis Pharmaceuticals	Completed	No outcome recorded
Phase 2	NCT01256411 Background	Nov 2010 → Apr 2012	essential hypertension	Novartis Pharmaceuticals	Completed	No outcome recorded
Phase 2	NCT00976495 Comparator	Oct 2009 → Nov 2010	type 2 diabetes mellitus	AstraZeneca	Completed	No outcome recorded
Phase 2	NCT00806585 Comparator	Dec 2008 → Mar 2010	hypertensive disorder, type 2 diabetes mellitus	Merck Sharp & Dohme LLC	Terminated	No outcome recorded
Phase 2	NCT00605072 Comparator	Jan 2008 → Dec 2011	cognitive impairment with or without cerebellar ataxia, hypertensive disorder	University of Southern California	Completed	No outcome recorded
Phase 2	NCT00282178 Comparator	Apr 2005 → Mar 2006	hypertensive disorder, obesity disorder	Umeå University	Completed	No outcome recorded

Phase 2/31 trial
Phase 2/3	NCT02072330 Comparator	Mar → Dec 2013	essential hypertension	Takeda	Completed	No outcome recorded
Phase 346 trials
Phase 3	NCT06608472 Comparator	Nov 2026 → Apr 2028 expected	essential hypertension	Eurofarma Laboratorios S.A.	Not yet recruiting	No outcome recorded
Phase 3	NCT05373264 Comparator	Jul 2024 → Jul 2030 expected	autosomal dominant polycystic kidney disease	University Medical Center Groningen	Recruiting	No outcome recorded
Phase 3	NCT05920005 Comparator	Aug 2023 → Mar 2025	hypertensive disorder	Hospital Israelita Albert Einstein	Completed	No outcome recorded
Phase 3	NCT04927299 Comparator	Jun 2022 → Aug 2023	essential hypertension	Laboratorios Silanes S.A. de C.V.	Completed	No outcome recorded
Phase 3	NCT01620788 Comparator	Nov 2019 → Jul 2023	hypertensive disorder	EMS	Suspended	No outcome recorded
Phase 3	NCT03928145 Comparator	Nov 2019 → Jul 2021	essential hypertension	Hospital de Clinicas de Porto Alegre	Unknown	No outcome recorded
Phase 3	NCT03660397 Background	Aug 2018 → Jul 2019	hypertensive disorder	Third Military Medical University	Unknown	No outcome recorded
Phase 3	NCT03298802 Comparator	Nov 2017 → Apr 2025	preeclampsia	The University of Texas Medical Branch, Galveston	Terminated	No outcome recorded
Phase 3	NCT02521246 Comparator	Nov 2016 → May 2017	essential hypertension	EMS	Withdrawn	No outcome recorded
Phase 3	NCT02521233 Comparator	Nov 2016 → May 2017	essential hypertension	EMS	Withdrawn	No outcome recorded
Phase 3	NCT02900729 Background	Oct 2016 → Aug 2017	hypertensive disorder	Shanghai WiseGain Medical Devices Co., Ltd.	Unknown	No outcome recorded
Phase 3	NCT02185417 Comparator	Jun 2016 → Oct 2022	hypertensive disorder	VA Office of Research and Development	Completed	No outcome recorded
Phase 3	NCT01647932 Comparator	Oct 2014 → Dec 2019	heart failure	Spanish Society of Internal Medicine	Completed	No outcome recorded
Phase 3	NCT04952051 Comparator	Jul 2014 → Jul 2019	hypertensive disorder	Second Affiliated Hospital, School of Medicine, Zhejiang University	Completed	No outcome recorded
Phase 3	NCT01838850 Background	Apr 2013 → Aug 2014	essential hypertension	Daiichi Sankyo	Completed	No outcome recorded
Phase 3	NCT01365481 Background	Aug 2011 → Sep 2015	chronic kidney disease, hypertensive disorder	Novartis Pharmaceuticals	Completed	No outcome recorded
Phase 3	NCT01415505 Background	Aug 2011 → Jan 2013	essential hypertension	Forest Laboratories	Completed	No outcome recorded
Phase 3	NCT01307033 Background	Mar 2011 → Dec 2012	hypertensive disorder	Organon and Co	Completed	No outcome recorded
Phase 3	NCT01309828 Comparator	Mar 2011 → Oct 2012	—	Takeda	Completed	No outcome recorded
Phase 3	NCT01271985 Comparator	Feb 2011 → Jan 2019	cardiovascular disorder	Tehran University of Medical Sciences	Completed	No outcome recorded
Phase 3	NCT01299376 Background	Jan → Nov 2011	hypertensive disorder	Merck Sharp & Dohme LLC	Completed	No outcome recorded
Phase 3	NCT01033071 Comparator	Jan → Oct 2010	essential hypertension	Takeda	Completed	No outcome recorded
Phase 3	NCT00996281 Comparator	Oct 2009 → Nov 2011	essential hypertension	Takeda	Completed	No outcome recorded
Phase 3	NCT01127217 Background	May 2009 → Mar 2010	hypertensive disorder	Hanmi Pharmaceutical Company Limited	Completed	No outcome recorded
Phase 3	NCT00867490 Background	Mar → Aug 2009	hypertensive disorder	Novartis	Completed	No outcome recorded
Phase 3	NCT00846365 Comparator	Mar 2009 → Jun 2010	essential hypertension	Takeda	Completed	No outcome recorded
Phase 3	NCT00797862 Background	Nov 2008 → Nov 2010	essential hypertension	Novartis	Completed	No outcome recorded
Phase 3	NCT00670787 Comparator	Jun 2008 → Nov 2010	hypertensive disorder	Kyushu University	Completed	No outcome recorded
Phase 3	NCT00649389 Comparator	May 2008 → Apr 2009	hypertensive disorder	Daiichi Sankyo	Completed	No outcome recorded
Phase 3	NCT00739674 Background	Feb 2008 → Jul 2009	essential hypertension	Organon and Co	Completed	No outcome recorded
Phase 3	NCT00695955 Background	Jun 2007 → May 2010	essential hypertension	Takeda	Completed	No outcome recorded
Phase 3	NCT00546754 Comparator	May 2007 → Apr 2009	hypertensive disorder	Organon and Co	Completed	No outcome recorded
Phase 3	NCT00446563 Comparator	Mar 2007 → Mar 2010	hypertensive heart disease	Novartis	Completed	No outcome recorded
Phase 3	NCT00368277 Background	Sep 2006 → Feb 2008	essential hypertension	Novartis Pharmaceuticals	Completed	No outcome recorded
Phase 3	NCT00360178 Background	Jul → Dec 2006	hypertensive disorder	Novartis	Completed	No outcome recorded
Phase 3	NCT00327145 Background	Mar 2006 → Jan 2007	hypertensive disorder	Novartis	Completed	No outcome recorded
Phase 3	NCT00220233 Background	Apr 2005 → Aug 2007	essential hypertension	Sankyo Pharma Gmbh	Completed	No outcome recorded
Phase 3	NCT00133185 Background	Mar 2004 → Mar 2005	hypertensive disorder	Boehringer Ingelheim	Completed	No outcome recorded
Phase 3	NCT00170950 Comparator	Oct 2003 → Jan 2008	hypertensive disorder	Novartis	Terminated	No outcome recorded
Phase 3	NCT00751829 Background	Jul 2003 → Oct 2004	—	Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company	Completed	No outcome recorded
Phase 3	NCT00751751 Background	Jun 2003 → Apr 2005	essential hypertension	Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company	Completed	No outcome recorded
Phase 3	NCT00185185 Background	Nov 2001 → Feb 2006	atherosclerotic cardiovascular disease, essential hypertension	Sankyo Pharma Gmbh	Completed	No outcome recorded
Phase 3	NCT02175355 Comparator	Oct 1999 → Aug 2000	hypertensive disorder	Boehringer Ingelheim	Completed	No outcome recorded
Phase 3	NCT02183701 Comparator	Apr → Dec 1998	hypertensive disorder	Boehringer Ingelheim	Completed	No outcome recorded
Phase 3	NCT00886600 Background	May 1991 → May 1992	hypertensive disorder	Merck Sharp & Dohme LLC	Completed	No outcome recorded
Phase 3	NCT02483936 Comparator	? → Jun 2025	essential hypertension	EMS	Withdrawn	No outcome recorded

Phase 471 trials
Phase 4	NCT07687160 Comparator	Sep 2026 → Feb 2028 expected	hypertensive disorder	Ottawa Hospital Research Institute	Not yet recruiting	No outcome recorded
Phase 4	NCT06041529 Comparator	Oct 2023 → Feb 2026 overdue	essential hypertension	Yuhan Corporation	Active not recruiting	No outcome recorded
Phase 4	NCT07271420 Comparator	Jan 2020 → Dec 2026 expected	end stage renal failure, hypertensive disorder	Chinese University of Hong Kong	Recruiting	No outcome recorded
Phase 4	NCT03640221 Comparator	Sep 2018 → May 2020	essential hypertension, type 2 diabetes mellitus	Cedars-Sinai Medical Center	Withdrawn	No outcome recorded
Phase 4	NCT03946514 Background	Sep 2018 → Aug 2024	hypertensive disorder	Shanghai Jiao Tong University School of Medicine	Completed	No outcome recorded
Phase 4	NCT03170336 Comparator	Mar 2018 → Aug 2020	chronic kidney disease	Guangdong Provincial People's Hospital	Completed	No outcome recorded
Phase 4	NCT04521023 Comparator	Sep 2017 → Jan 2020	hypertensive disorder	Chong Kun Dang Pharmaceutical	Completed	No outcome recorded
Phase 4	NCT03294070 Background	Sep 2017 → Mar 2018	hypertensive disorder	Centro Universitario de Ciencias de la Salud, Mexico	Unknown	No outcome recorded
Phase 4	NCT03109795 Comparator	Apr 2017 → Jun 2023	anxiety, hypertensive disorder	University of Iowa	Terminated	No outcome recorded
Phase 4	NCT03578042 Comparator	Apr 2017 → Sep 2019	hypertensive disorder	Hotel Dieu de France Hospital	Unknown	No outcome recorded
Phase 4	NCT02774460 Comparator	Feb 2017 → Jun 2021	hypertensive disorder	Uppsala University	Completed	No outcome recorded
Phase 4	NCT02875886 Comparator	Sep 2016 → Apr 2018	chronic kidney disease	Erasmus Medical Center	Completed	No outcome recorded
Phase 4	NCT01748123 Comparator	Aug 2016 → Jun 2017	hypertensive disorder	Johns Hopkins University	Withdrawn	No outcome recorded
Phase 4	NCT02817503 Background	Dec 2015 → Dec 2016	hyperhomocysteinemia, hypertensive disorder	Second Affiliated Hospital of Nanchang University	Unknown	No outcome recorded
Phase 4	NCT02214498 Comparator	May 2015 → May 2017	essential hypertension	Erasmus Medical Center	Unknown	No outcome recorded
Phase 4	NCT01922141 Background	May 2015 → Jun 2018	hypertensive disorder	Novartis Pharmaceuticals	Withdrawn	No outcome recorded
Phase 4	NCT02427880 Background	Apr → Jun 2015	nephrotic syndrome	Shiraz University of Medical Sciences	Completed	No outcome recorded
Phase 4	NCT02433119 Comparator	Mar 2015 → Sep 2016	hypertensive disorder	Dong-A ST Co., Ltd.	Completed	No outcome recorded
Phase 4	NCT02373163 Comparator	Sep 2014 → Mar 2016	hypertensive disorder	Prevencion	Completed	No outcome recorded
Phase 4	NCT01822860 Comparator	Mar 2013 → Feb 2015	hypertensive disorder	Creighton University	Withdrawn	No outcome recorded
Phase 4	NCT01819441 Background	May 2012 → Dec 2016	cerebrovascular disorder	Yining Huang	Unknown	No outcome recorded
Phase 4	NCT00987662 Comparator	Jan 2012 → Jan 2013	hypertensive disorder, obesity disorder	Aristotle University Of Thessaloniki	Withdrawn	No outcome recorded
Phase 4	NCT02046395 Background	Jan 2012 → Dec 2019	hypertensive disorder, type 2 diabetes mellitus	Tulane University School of Medicine	Completed	No outcome recorded
Phase 4	NCT01519635 Comparator	Oct 2011 → Oct 2014	hypertensive disorder	Centre Hospitalier Universitaire Vaudois	Completed	No outcome recorded
Phase 4	NCT01030458 Comparator	Sep 2010 → Mar 2012	hypertensive disorder	KU Leuven	Completed	No outcome recorded
Phase 4	NCT01172431 Comparator	Sep 2010 → Mar 2012	hypertensive disorder, impaired renal function disease	West China Hospital	Completed	No outcome recorded
Phase 4	NCT01180205 Comparator	Aug 2010 → Oct 2011	hypertensive disorder	Johannes Gutenberg University Mainz	Unknown	No outcome recorded
Phase 4	NCT01828359 Comparator	Aug 2010 → Jan 2013	essential hypertension	Hanmi Pharmaceutical Company Limited	Completed	No outcome recorded
Phase 4	NCT01176032 Background	Jun 2010 → Apr 2013	hypertensive disorder, hypertensive heart disease	Novartis Pharmaceuticals	Completed	No outcome recorded
Phase 4	NCT01101009 Comparator	Apr 2010 → Nov 2012	hypertensive disorder	Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company	Completed	No outcome recorded
Phase 4	NCT01271374 Comparator	Apr 2010 → Jun 2011	hypertensive disorder	InVasc Therapeutics, Inc.	Unknown	No outcome recorded
Phase 4	NCT00438113 Comparator	Dec 2009 → Sep 2016	atrial fibrillation	Nova Scotia Health Authority	Completed	No outcome recorded
Phase 4	NCT00994253 Comparator	Aug 2009 → Dec 2012	hypertensive disorder, type 2 diabetes mellitus	Corewell Health East	Withdrawn	No outcome recorded
Phase 4	NCT03115853 Background	Jun 2009 → Jan 2012	hypertensive disorder	Vanderbilt University Medical Center	Completed	No outcome recorded
Phase 4	NCT00760266 Comparator	Sep 2008 → Apr 2009	hypertensive disorder	Novartis	Completed	No outcome recorded
Phase 4	NCT00744237 Comparator	Aug 2008 → Jul 2010	hypertensive disorder, type 2 diabetes mellitus	Forest Laboratories	Completed	No outcome recorded
Phase 4	NCT00708344 Comparator	Jun 2008 → Jul 2009	hypertensive disorder	Sanofi	Completed	No outcome recorded
Phase 4	NCT00673790 Comparator	May 2008 → Jul 2010	hypertensive disorder	Forest Laboratories	Completed	No outcome recorded
Phase 4	NCT00980187 Comparator	Mar 2008 → Aug 2010	hypertensive disorder, type 2 diabetes mellitus	LaborMed Pharma S.A.	Completed	No outcome recorded
Phase 4	NCT00605202 Comparator	Feb 2008 → Jan 2009	potassium deficiency	University of Oulu	Completed	No outcome recorded
Phase 4	NCT01011660 Comparator	Oct 2007 → Aug 2012	essential hypertension	Chinese Academy of Medical Sciences, Fuwai Hospital	Unknown	No outcome recorded
Phase 4	NCT00745953 Comparator	Aug 2007 → Aug 2009	metabolic syndrome X	University of Texas Southwestern Medical Center	Withdrawn	No outcome recorded
Phase 4	NCT00500604 Background	Jul 2007 → Jan 2010	hypertensive disorder	Sanofi	Completed	No outcome recorded
Phase 4	NCT00509470 Comparator	Jul 2007 → Jun 2012	essential hypertension	Tokyo University	Completed	No outcome recorded
Phase 4	NCT01375322 Comparator	Jun 2007 → Jun 2010	hypertensive disorder, proteinuria, type 2 diabetes mellitus	TSH Biopharm Corporation Limited	Completed	No outcome recorded
Phase 4	NCT00887510 Comparator	May 2007 → Nov 2009	hypertensive disorder	University of Florida	Completed	No outcome recorded
Phase 4	NCT00468923 Comparator	May 2007 → Dec 2015	stroke disorder	Population Health Research Institute	Completed	No outcome recorded
Phase 4	NCT00775814 Comparator	Oct 2006 → Sep 2008	hypertensive disorder, obesity disorder	Takeda	Completed	No outcome recorded
Phase 4	NCT00369538 Comparator	Aug 2006 → ?	end stage renal failure, hypertensive disorder, proteinuria	University Hospital, Strasbourg, France	Suspended	No outcome recorded
Phase 4	NCT00362037 Background	Mar 2006 → Jun 2008	essential hypertension	Sanofi	Completed	No outcome recorded
Phase 4	NCT00362258 Background	Feb 2006 → Sep 2008	hypertensive disorder	Sanofi	Completed	No outcome recorded
Phase 4	NCT00263393 Background	Dec 2005 → Dec 2008	coronary artery disorder, diabetes mellitus, myocardial infarction, stroke disorder	The George Institute	Completed	No outcome recorded
Phase 4	NCT00277472 Comparator	Nov 2005	hypertensive disorder	Novartis	Completed	No outcome recorded
Phase 4	NCT00110422 Comparator	Nov 2005 → Feb 2007	hypertensive disorder, metabolic syndrome X	Bristol-Myers Squibb	Completed	No outcome recorded
Phase 4	NCT00661895 Background	Aug 2005 → Aug 2009	hypertensive disorder	Creighton University	Completed	No outcome recorded
Phase 4	NCT00171600 Background	Jul 2005 → Jan 2007	diabetic kidney disease, hypertensive disorder	Novartis	Terminated	No outcome recorded
Phase 4	NCT00224549 Background	Apr 2005 → Aug 2009	essential hypertension	Assistance Publique - Hôpitaux de Paris	Completed	No outcome recorded
Phase 4	NCT00171574 Background	Nov 2004 → Jul 2006	diabetic kidney disease, hypertensive disorder	Novartis	Completed	No outcome recorded
Phase 4	NCT00171132 Background	Aug 2004 → Aug 2007	hypertensive disorder	Novartis	Completed	No outcome recorded
Phase 4	NCT00131846 Comparator	Apr 2004 → Aug 2012	essential hypertension	Kyoto University	Completed	No outcome recorded
Phase 4	NCT00234858 Comparator	Mar 2004 → Apr 2006	hypertensive disorder, metabolic syndrome X	Abbott	Completed	No outcome recorded
Phase 4	NCT00232882 Comparator	Dec 2003 → Apr 2006	essential hypertension	Montreal Clinical Research Institute	Completed	No outcome recorded
Phase 4	NCT00140959 Background	Feb 2003 → Jun 2004	hypertensive disorder	Organon and Co	Completed	No outcome recorded
Phase 4	NCT00239538 Background	Jan 2003 → Dec 2004	hypertensive disorder, type 2 diabetes mellitus	Boehringer Ingelheim	Completed	No outcome recorded
Phase 4	NCT00240474 Background	Dec 2002 → Mar 2004	hypertensive disorder	Boehringer Ingelheim	Completed	No outcome recorded
Phase 4	NCT00651287 Comparator	Dec 2002 → Jun 2004	hypertensive disorder	Pfizer	Completed	No outcome recorded
Phase 4	NCT00772499 Comparator	Nov 2002 → Jul 2005	essential hypertension	Daiichi Sankyo	Completed	No outcome recorded
Phase 4	NCT00274638 Background	Jul 2002 → Jul 2003	hypertensive disorder	Boehringer Ingelheim	Completed	No outcome recorded
Phase 4	NCT03276598 Comparator	Nov 1999 → Apr 2004	essential hypertension	Helsinki University Central Hospital	Completed	No outcome recorded
Phase 4	NCT00813722 Comparator	Mar 1999 → Jan 2009	hypertensive disorder	University of Sao Paulo	Unknown	No outcome recorded
Phase 4	NCT00487123 Background	? → Sep 2007	essential hypertension	Novartis	Completed	No outcome recorded

Phase not applicable23 trials
—	NCT07683585 Comparator	Apr → Jul 2026 overdue	coronary artery disorder, hypertensive disorder	National Medical Research Center for Therapy and Preventive Medicine	Recruiting	No outcome recorded
—	NCT07458880 Comparator	Mar 2026 → Sep 2029 expected	intracerebral hemorrhage	The University of Hong Kong	Recruiting	No outcome recorded
—	NCT06362668 Comparator	May → Oct 2024	heart failure	Reprieve Cardiovascular, Inc	Completed	No outcome recorded
—	NCT05684055 Comparator	Sep 2023 → May 2025 overdue	hypertensive disorder	University Hospital, Basel, Switzerland	Active not recruiting	No outcome recorded
—	NCT03261375 Background	Jan 2021 → Dec 2022	essential hypertension	Shanghai Golden Leaf MedTec Co. Ltd	Completed	No outcome recorded
—	NCT03951558 Comparator	May 2018 → Jun 2019	idiopathic hypercalciuria, nephrolithiasis	Hospital Infantil de Mexico Federico Gomez	Unknown	No outcome recorded
—	NCT03015311 Background	Jan 2017 → Dec 2020	essential hypertension	Chinese Academy of Medical Sciences, Fuwai Hospital	Unknown	No outcome recorded
—	NCT03082742 Comparator	Aug 2015 → Jun 2018	chronic kidney disease, secondary hyperparathyroidism of renal origin	University of Sao Paulo General Hospital	Unknown	No outcome recorded
—	NCT06681116 Comparator	Feb 2015 → Aug 2020	idiopathic hypercalciuria, nephrolithiasis, calcium oxalate	ALI KAMAL M. SAMI	Completed	No outcome recorded
—	NCT02412761 Comparator	Jun 2013 → Jul 2016	essential hypertension	The University of Texas Health Science Center, Houston	Completed	No outcome recorded
—	NCT01996085 Comparator	Jan 2013 → Jun 2016	hypertensive disorder	Military Institute od Medicine National Research Institute	Completed	No outcome recorded
—	NCT01661777 Comparator	Aug 2012 → Aug 2013	endolymphatic hydrops, eustachian tube disorder	Vanderbilt University	Withdrawn	No outcome recorded
—	NCT01425242 Background	Sep 2011 → Dec 2013	abdominal aortic aneurysm, essential hypertension	Amsterdam UMC, location VUmc	Terminated	No outcome recorded
—	NCT01258764 Comparator	Nov 2010 → Mar 2014	hypertensive disorder	Scripps Translational Science Institute	Completed	No outcome recorded
—	NCT00999752 Comparator	Oct 2009 → Feb 2010	hypertensive disorder	InVasc Therapeutics, Inc.	Completed	No outcome recorded
—	NCT00865124 Comparator	Sep 2008 → Aug 2013	type 2 diabetes mellitus, vascular disorder	Brigham and Women's Hospital	Completed	No outcome recorded
—	NCT00478335 Background	May 2007 → Oct 2012	nephrogenic diabetes insipidus	University of Colorado, Denver	Completed	No outcome recorded
—	NCT02336607 Comparator	Dec 2005 → Jun 2006	hypertensive disorder	AstraZeneca	Completed	No outcome recorded
—	NCT00617877 Background	Mar 2005 → Jun 2009	hypertensive disorder	Merck Sharp & Dohme LLC	Completed	No outcome recorded
—	NCT00160160 Background	Oct 2004 → ?	hypertensive disorder, type 2 diabetes mellitus	Solvay Pharmaceuticals	Completed	No outcome recorded
—	NCT00229242 Comparator	Nov 2003 → Dec 2006	hypertensive disorder	Queen's University	Completed	No outcome recorded
—	NCT00684489 Comparator	Sep 2003 → Mar 2005	essential hypertension	Medical University of South Carolina	Completed	No outcome recorded
—	NCT00214825 Comparator	Aug 2003 → Mar 2006	diabetes mellitus, proteinuria	Brigham and Women's Hospital	Completed	No outcome recorded

Press releases naming this drug 3 releases

Date	Issuer	Release
2010-04-07	Teva Branded Pharmaceutical Products R&D, Inc.	Teva Announces Final Approval of Generic Hyzaar® and Cozaar® tevapharm.com ↗
2010-03-02	Teva Branded Pharmaceutical Products R&D, Inc.	Teva Announces Favorable Court Ruling in Generic Hyzaar® and Cozaar® Litigation tevapharm.com ↗
2006-06-14	Teva Branded Pharmaceutical Products R&D, Inc.	Teva Announces Tentative Approval of Losartan Potassium & Hydrochlorothiazide Tablets tevapharm.com ↗

Evidence & citations 16 cited values

Every value below carries the sentence it was read from. 433 sources stand behind the page.

Field	Value	Cited text
Known as	hydrochlorothiazide	“This is a phase III, non-inferiority, randomized, double-blind, double-dummy, active-controlled, multicenter study to compare the efficacy and safety of N0877 versus double...” NCT06608472 ↗ 383 “The participant's blood pressure medication regimen will then be altered to initiate a thiazide-type (hydrochlorothiazide or chlorthalidone) or loop diuretic (furosemide,...” NCT04192110 ↗ “OBJECTIVE: To compare the antihypertensive efficacy and safety of once-daily triple therapy with amlodipine (Aml) 10 mg, valsartan (Val) 320 mg, and hydrochlorothiazide (HCTZ)...” PMID 23721363 ↗ Jul 2013 “The purpose of this trial is to evaluate the safety and efficacy of combination therapy of aliskiren/hydrochlorothiazide (HCTZ) 150/25 mg and 300/25 mg compared with HCTZ 25 mg...” NCT00387517 ↗ “Antihypertensive Effects of a Fixed-dose Combination of Losartan and Hydrochlorothiazide Plus Amlodipine Versus a Hydrochlorothiazide and Atenolol Combination Plus Amlodipine...” NCT00140959 ↗ “A Study on the Efficacy and Safety of Olmesartan Medoxomil and Its Combination With Hydrochlorothiazide Compared With an ACE Inhibitor and Its Combination With a Calcium...” NCT00185120 ↗ “Then, losartan 50 mg for 4 weeks, then titrate to losartan 100 mg at Week 4, then titrate to losartan 100 mg + hydrochlorothiazide (HCTZ) 12.5 mg at Week 8, and finally titrate...” NCT00289887 ↗ “Participants will be randomized to one of three first-line antihypertensive agents: (1) the ACE inhibitor perindopril, (2) the AT1 receptor antagonist losartan, or (3) the...” PMID 32039215 ↗ Jan 2020 “COZAAR Plus (Losartan Potassium 50mg/Hydrochlorothiazide 12.5mg) Possibly Titrated up to COZAAR Plus-F (Losartan Potassium 100mg/Hydrochlorothiazide 25mg) in Patients With...” NCT00449111 ↗ “Successful treatment of hypertension accounts for improvements in markers of diastolic function - a pilot study comparing hydrochlorothiazide-based and amlodipine-based...” PMID 19960134 ↗ Dec 2009 “In intervention clusters, lay CHWs independently prescribed and titrated a fixed-dose combination of amlodipine and hydrochlorothiazide, guided by a mobile clinical decision...” PMID 41680483 ↗ Feb 2026 “Two randomized studies were designed to assess the safety, tolerability and efficacy of losartan 100 mg (L100) plus hydrochlorothiazide 12.5 mg (H12.5) in a single fixed-dose...” PMID 24990091 ↗ Jul 2014 “Antihypertensive treatment with low-dose thiazide diuretics at 12.5 mg/day of hydrochlorothiazide or equivalent (Diuretics group) or that without thiazide diuretics...” PMID 25031188 ↗ Jul 2014 “Comparing a Fixed Dose Combination of Telmisartan 80mg Plus Hydrochlorothiazide 12.5mg to Telmisartan 80mg in Patients Who Fail to Respond Adequately to Treatment With Telmisartan 80mg.” NCT00146341 ↗ “This study aimed to evaluate the long-term safety and efficacy of a triple combination therapy with 20 mg azilsartan (AZL), 5 mg amlodipine (AML) and 12.5 mg hydrochlorothiazide (HCTZ).” PMID 29235365 ↗ Dec 2017 “Version 1 contains aspirin 75mg, simvastatin 40mg, Lisinopril 10mg and Atenolol 50mg; Version 2 contains aspirin 75mg, simvastatin 40mg, Lisinopril 10mg and Hydrochlorothiazide 12.5mg.” NCT01057537 ↗ “Version 1 contains aspirin 75mg, simvastatin 40mg, Lisinopril 10mg and Atenolol 50mg; Version 2 contains aspirin 75mg, simvastatin 40mg, Lisinopril 10mg and Hydrochlorothiazide 12.5mg.” NCT01326676 ↗ “4 weeks treatment with candesartan 32 mg (two 16 mg tablets) plus hydrochlorothiazide 25 mg (two 12.5 mg tablets) taken orally with water in the morning between 7 and 10 am.” NCT00867490 ↗ “comparing valsartan monotherapy with valsartan/hydrochlorothiazide (HCTZ) combination therapy as initial treatment for high-risk patients with stage 2 hypertension” PMID 18498915 ↗ Apr 2008 “Other drugs, including CCB (amlodipine preferred), diuretics (hydrochlorothiazide preferred), and β-blockers, are allowed, in order to achieve the SBP target.” NCT02817503 ↗ “run-in treatment period with telmisartan 80 mg plus hydrochlorothiazide 12.5 mg (T80/H12.5) taken as a single tablet once per day for approximately six weeks.” NCT00239369 ↗ “A combination tablet containing Aspirin 81 mg, enalapril 5 mg (or valsartan 40 mg), atorvastatin 20 mg and hydrochlorothiazide 12.5 mg taken once daily” NCT01271985 ↗ “Japanese patients with uncontrolled essential hypertension received single-blind losartan 50 mg/hydrochlorothiazide 12.5 mg (L50/H12.5) for 8 weeks.” PMID 25271811 ↗ Oct 2014 “Decongestive therapy with e.v. furosemide +/- hydrochlorothiazide will be adjusted by intraabdominal pressure and/or point of care ultrasound” NCT07008365 ↗ “A capsule of Polycap ® contains 100mg of Aspirin, 20mg of simvastatin, 12.5mg hydrochlorothiazide, 5mg of ramipril and 50mg of atenolol.” NCT05963568 ↗ “The trial compared a Polypill (75 mg aspirin, 20 mg simvastatin, 10 mg lisinopril and 12.5 mg hydrochlorothiazide) to Standard Practice.” PMID 21205325 ↗ Jan 2011 “polypill (containing 40 mg of simvastatin, 100 mg of atenolol, 25 mg of hydrochlorothiazide, and 10 mg of ramipril) or placebo daily” PMID 33186492 ↗ Nov 2020 “The mainstays of management of endolymphatic hydrops are a low sodium diet and diuretic treatment (hydrochlorothiazide/triamterene).” NCT01661777 ↗ “The polypill comprises hydrochlorothiazide 12.5 mg, aspirin 81 mg, atorvastatin 20 mg, and either enalapril 5 mg or valsartan 40 mg.” PMID 32894967 ↗ Aug 2020 “A capsule of Polycap contained aspirin 100 mg, simvastatin 20 mg, hydrochlorothiazide 12.5 mg, ramipril 5 mg, and atenolol 50 mg.” PMID 39082406 ↗ Jul 2024 “the cardiovascular polypill (aspirin 75 mg, simvastatin 40 mg, lisinopril 10 mg, and hydrochlorothiazide 12.5 mg) in the evening” PMID 23382539 ↗ Feb 2013 “The amlodipine/benazepril and benazepril/hydrochlorothiazide dual therapies were comparable in ambulatory systolic BP lowering.” PMID 38263021 ↗ Jan 2024 “Candesartan/Hydrochlorothiazide(Candemore Plus® Tab) Versus Candesartan/Amlodipine(Cantabell® Tab) in Hypertensive Patients” NCT04521023 ↗ “Fixed dose combination therapy - aspirin 81mg, hydrochlorothiazide 12.5mg, enalapril 2.5mg and atorvastatin 20mg Once daily” NCT00603590 ↗ “Drugs used were hypertension medications were: chlorothiazide, hydrochlorothiazide, polythiazide indapamide, metolazone” NCT00684489 ↗ “comparing hydrochlorothiazide 25-50 mg, amiloride 10-20 mg and combination of both diuretics at half these doses.” PMID 26253567 ↗ Aug 2015 “Each pill contains acetylsalicylic acid 81 mg, atorvastatin 20 mg, hydrochlorothiazide 12.5 mg, valsartan 40 mg” NCT01245608 ↗ “hydrochlorothiazide (HCTZ) is a drug indicated for the treatment of patients with mild to moderate hypertension” NCT01294631 ↗ “Coated, Oral tablet containing Olmesartan medoxomil(OM)-Hydrochlorothiazide(HCTZ) 20-12.5mg, given once a day.” NCT01838850 ↗ “One hydrochlorothiazide 12.5 mg tablet + one hydrochlorothiazide 12.5 mg placebo tablet taken once per day.” NCT00923091 ↗ “Other drugs, including hydrochlorothiazide and β-blockers, are allowed, in order to achieve the SBP target.” NCT03015311 ↗ “valsartan 160 mg once a day for 6 months plus hydrochlorothiazide 25 mg a tablet once a day for 6 months” NCT00687206 ↗ “Atenolol 100 mg for 4 weeks followed by atenolol 100 mg + hydrochlorothiazide 12.5 mg for 4 weeks” NCT00232882 ↗ “Treatment with irbesartan 300mg for 4 weeks. IF ABP\>135/85 mmHg add hydrochlorothiazide 12.5 mg.” NCT00987662 ↗ “After 4 weeks of titration, hydrochlorothiazide 12.5 mg could be optionally added to both groups.” PMID 22035131 ↗ Oct 2011 “Hydrochlorothiazide, metolazone, chlorthalidone, chlorothiazide, bendroflumethiazide, indapamide” NCT04330300 ↗ “Polipill version 2: aspirin 75mg, simvastatin 40mg, lisinopril 10mg, hydrochlorothiazide 12.5mg.” NCT01313702 ↗ “single-pill combination of the direct renin inhibitor aliskiren and hydrochlorothiazide (HCT)” PMID 19203020 ↗ Dec 2008 “candesartan at a dose of 16 mg per day plus hydrochlorothiazide at a dose of 12.5 mg per day” PMID 27041480 ↗ Apr 2016 “Tablet containing losartan potassium (100 mg) and hydrochlorothiazide (12.5 mg), once daily” NCT01307046 ↗ “Telmisartan 80 mg/Amlodipine 5 mg/Hydrochlorothiazide 12.5 mg Fixed-dose Combination Tablet” NCT02183675 ↗ “Encapsulated Hydrochlorothiazide 12.5 mg or 25 mg total daily dosage, oral administration” NCT00673790 ↗ “Thereafter addition of semaglutide, pentoxifylline, hydrochlorothiazide, and baricitinib.” NCT05897372 ↗ “either a combined pill of ACE inhibitors and diuretics (Hydrochlorothiazide/Lisinopril)” NCT05049616 ↗ “Step IV: olmesartan 20 mg or 40 mg + amlodipine 10 mg + hydrochlorothiazide 12.5 mg” NCT03024476 ↗ “Step 2: Combination drug containing losartan 50 mg and hydrochlorothiazide 12.5 mg” NCT01198496 ↗ “Olmesartanmedoxomil (OM) /Hydrochlorothiazide (HCTZ)40/12.5 mg tablets once daily” NCT00441350 ↗ “Valsartan 160mg and Hydrochlorothiazide 12.5mg, tablet, once a day for 8 weeks” NCT02433119 ↗ “telmisartan 80 mg + hydrochlorothiazide (HCTZ) 12.5 mg fixed dose combination” NCT01911780 ↗ “one 12.5 mg hydrochlorothiazide (HCTZ) tablet daily, orally, for 12 weeks.” NCT00806585 ↗ “once daily Telmisartan 80 mg/Hydrochlorothiazide 12.5 mg (Micardis Plus)” NCT00257491 ↗ “Step 2 - combination of Accupril with Hydrochlorothiazide 12.5 mg po od.” NCT00438113 ↗ “hydrochlorothiazide and angiotensin receptor blocker (valsartan) therapy” PMID 20498618 ↗ Aug 2010 “combination valsartan/hydrochlorothiazide (HCTZ) vs. amlodipine/HCTZ” PMID 21974760 ↗ Jul 2011 “Fixed dose Combination of Fimasartan/Amlodipine/Hydrochlorothiazide” NCT03629067 ↗ “500 mg BID + hydrochlorothiazide (HCTZ) 25 mg once daily \[QD\]” NCT03198793 ↗ “amlodipine 10mg + irbesartan 300mg + hydrochlorothiazide 12.5mg” NCT06790927 ↗ “Losartan 50 mg / Hydrochlorothiazide (HCTZ) 12.5 mg Combination” NCT01431508 ↗ “Fimasartan/Hydrochlorothiazide combination 60/12.5mg 120/12.5mg” NCT01258673 ↗ “amiloride/hydrochlorothiazide 1.25-2.5 mg/12.5-25 mg (Group A)” PMID 22329591 ↗ Apr 2012 “CoAprovel (300/12.5mg hydrochlorothiazide one per day per os.” NCT00362037 ↗ “irbesartanhydrochlorothiazide 162.5 mg/d, amlodipine 5 mg/d” NCT03660397 ↗ “valsartan/hydrochlorothiazide (HCTZ) combination therapy” NCT00698646 ↗ “160+12,5 mg valsartan+hydrochlorothiazide combination” NCT01425411 ↗ “Hydrochlorothiazide 12.5 mg p.o. tablet once daily” NCT01425242 ↗ “CoAprovel (300/12.5mg hydrochlorothiazide)” NCT00362258 ↗ “CoAprovel (300/12.5mg hydrochlorothiazide)” NCT00335673 ↗ “Telmisartan / Hydrochlorothiazide (HCTZ)” NCT02262780 ↗ “hydrochlorothiazide 25 mg/day (ESIDREX®)” NCT02824718 ↗ “Hydrochlorothiazide (25 mg) Monotherapy” NCT00277472 ↗ “hydrochlorothiazide (HCT G.L) 25mg” NCT06710600 ↗ “Nifedipine + hydrochlorothiazide” NCT03261375 ↗ “hydrochlorothiazide [thiazide]” PMID 37039792 ↗ Apr 2023 “Hydrochlorothiazide (HCTZ)” NCT01302899 ↗ “Hydrochlorothiazide (HCTZ)” NCT01113047 ↗ “Hydrochlorothiazide (HCTZ)” NCT01259297 ↗ “Drug: Hydrochlorothiazide” NCT01180205 ↗ “HCTZ-hydrochlorothiazide” NCT00574834 ↗ “Hydrochlorothiazide25mg” NCT00926289 ↗ “Hydrochlorothiazide” NCT00459056 ↗ “hydrochlorothiazide” NCT02765009 ↗ NCT07271420 ↗ NCT00690521 ↗ NCT00307060 ↗ NCT00267943 ↗ NCT05171686 ↗ NCT00896389 ↗ NCT00110422 ↗ NCT00185185 ↗ NCT00649389 ↗ NCT00654745 ↗ NCT03658850 ↗ NCT00923533 ↗ NCT03179163 ↗ NCT00813722 ↗ NCT01138423 ↗ NCT00638482 ↗ NCT00649441 ↗ NCT01977430 ↗ NCT06681116 ↗ NCT00846365 ↗ NCT03109795 ↗ NCT03082742 ↗ NCT01922141 ↗ NCT00220233 ↗ NCT01176032 ↗ NCT03276598 ↗ NCT01256411 ↗ NCT04423627 ↗ NCT00535925 ↗ NCT00886600 ↗ NCT02294539 ↗ NCT00398541 ↗ NCT00605202 ↗ NCT00368277 ↗ NCT00760266 ↗ NCT00185172 ↗ NCT01370655 ↗ NCT02217852 ↗ NCT00649324 ↗ NCT02046395 ↗ NCT00223717 ↗ NCT00430950 ↗ NCT00617877 ↗ NCT00443612 ↗ NCT01767259 ↗ NCT00642096 ↗ NCT01309828 ↗ NCT00403481 ↗ NCT02336607 ↗ NCT06362668 ↗ NCT05920005 ↗ NCT03921736 ↗ NCT00648011 ↗ NCT04934228 ↗ NCT00171782 ↗ NCT01101009 ↗ NCT00847834 ↗ NCT03946514 ↗ NCT00426478 ↗ NCT00185068 ↗ NCT02466490 ↗ NCT00162474 ↗ NCT02744456 ↗ NCT00388388 ↗ NCT00865124 ↗ NCT00171561 ↗ NCT04242758 ↗ NCT02646397 ↗ NCT00976495 ↗ NCT02100462 ↗ NCT04676399 ↗ NCT00400218 ↗ NCT00942994 ↗ NCT06083116 ↗ NCT00171132 ↗ NCT00890591 ↗ NCT00887510 ↗ NCT00649233 ↗ NCT00171054 ↗ NCT03892148 ↗ NCT02278471 ↗ NCT02373163 ↗ NCT00871871 ↗ NCT00306696 ↗ NCT03254849 ↗ NCT03971929 ↗ NCT00171015 ↗ NCT00170989 ↗ NCT02187523 ↗ NCT00765947 ↗ NCT00492128 ↗ NCT00670566 ↗ NCT00980187 ↗ NCT00667719 ↗ NCT00835042 ↗ NCT00139698 ↗ NCT01276288 ↗ NCT01149473 ↗ NCT07020104 ↗ NCT01302691 ↗ NCT00170937 ↗ NCT01983462 ↗ NCT02276378 ↗ NCT00605072 ↗ NCT00821574 ↗ NCT01149486 ↗ NCT00651287 ↗ NCT00374855 ↗ NCT00360178 ↗ NCT01658657 ↗ NCT00496834 ↗ NCT04927299 ↗ NCT01822860 ↗ NCT00478335 ↗ NCT06491940 ↗ NCT02255253 ↗ NCT00424801 ↗ NCT01692717 ↗ NCT03578042 ↗ NCT01019590 ↗ NCT07683585 ↗ NCT00280540 ↗ NCT00383929 ↗ NCT05443932 ↗ NCT00446563 ↗ NCT00412932 ↗ NCT02185417 ↗ NCT00170950 ↗ NCT00548067 ↗ NCT02172586 ↗ NCT04465123 ↗ NCT00000525 ↗ NCT00872586 ↗ NCT02072330 ↗ NCT00447603 ↗ NCT00791258 ↗ NCT02711670 ↗ NCT00239538 ↗ NCT03889145 ↗ NCT02183701 ↗ NCT00834600 ↗ NCT02742467 ↗ NCT00765674 ↗ NCT00745953 ↗ NCT02377661 ↗ NCT04952051 ↗ NCT00274638 ↗ NCT01692301 ↗ NCT00092209 ↗ NCT01033071 ↗ NCT00224549 ↗ NCT04654312 ↗ NCT03170336 ↗ NCT00430638 ↗ NCT00751829 ↗ NCT00168779 ↗ NCT07458880 ↗ NCT00509470 ↗ NCT00797862 ↗ NCT00367094 ↗ NCT00247910 ↗ NCT00751751 ↗ NCT00396656 ↗ NCT02222480 ↗ NCT01480791 ↗ NCT00695955 ↗ NCT00311740 ↗ NCT03390465 ↗ NCT00546754 ↗ NCT06205407 ↗ NCT02900729 ↗ NCT00822107 ↗ NCT01858610 ↗ NCT00775814 ↗ NCT02521246 ↗ NCT01858623 ↗ NCT00400777 ↗ NCT04182854 ↗ NCT00999752 ↗ NCT04371874 ↗ NCT02214498 ↗ NCT00263393 ↗ NCT00649038 ↗ NCT00250562 ↗ NCT01415505 ↗ NCT00234858 ↗ NCT02710071 ↗ NCT03461003 ↗ NCT00708344 ↗ NCT00311155 ↗ NCT00523744 ↗ NCT00430508 ↗ NCT00739596 ↗ NCT00787605 ↗ NCT03387657 ↗ NCT01020214 ↗ NCT00241007 ↗ NCT03147092 ↗ NCT01748123 ↗ NCT01647932 ↗ NCT00739674 ↗ NCT01819441 ↗ NCT00263003 ↗ NCT00369538 ↗ NCT01012479 ↗ NCT07544888 ↗ NCT00402103 ↗ NCT00386607 ↗ NCT06041529 ↗ NCT02962258 ↗ NCT00795847 ↗ NCT05373264 ↗ NCT00705575 ↗ NCT02739672 ↗ NCT01365481 ↗ NCT00996281 ↗ NCT00621153 ↗ NCT00240448 ↗ NCT00240474 ↗ NCT07469722 ↗ NCT00153049 ↗ NCT00902304 ↗ NCT01198249 ↗ NCT00649597 ↗ NCT03978884 ↗ NCT01819220 ↗ NCT00834067 ↗ NCT02493322 ↗ NCT01030458 ↗ NCT01070030 ↗ NCT01519635 ↗ NCT00607035 ↗ NCT00772499 ↗ NCT00670787 ↗ NCT02699125 ↗ NCT00902538 ↗ NCT01767298 ↗ NCT00282178 ↗ NCT00214825 ↗ NCT05917275 ↗ NCT00500604 ↗ NCT00157963 ↗ NCT00338936 ↗ NCT03246555 ↗ NCT00273299 ↗ NCT07687160 ↗ NCT03928145 ↗ NCT03057431 ↗ NCT02738632 ↗ NCT07593612 ↗ NCT02175355 ↗ NCT00434967 ↗ NCT00797316 ↗ NCT00818883 ↗ NCT02412761 ↗ NCT02177500 ↗ NCT00327145 ↗ NCT02177487 ↗ NCT01996085 ↗ NCT02177435 ↗ NCT00671424 ↗ NCT00994253 ↗ NCT00133692 ↗ NCT02875886 ↗ NCT03032315 ↗ NCT03951558 ↗ NCT02483936 ↗ NCT01103245 ↗ NCT01375322 ↗ NCT00133185 ↗ NCT02177422 ↗ NCT01975246 ↗ NCT04197622 ↗ NCT03640221 ↗ NCT00355589 ↗ NCT07634068 ↗ NCT00246519 ↗ NCT00994617 ↗ NCT00700583 ↗ NCT06111885 ↗ NCT00354991 ↗ NCT00772577 ↗ NCT00546052 ↗ NCT02427880 ↗ NCT00661895 ↗ NCT02521233 ↗ NCT01258764 ↗ NCT00457483 ↗ NCT01172431 ↗ NCT00649688 ↗ NCT03423355 ↗ NCT03298802 ↗ NCT00487123 ↗
Known as	Diazide	“Diazide” NCT00621153 ↗
Known as	Dichlozid	“Dichlozid 1 Tab.(Hydrochlorothiazide 25.0 mg) would be administered orally once” NCT02739672 ↗ 1 “Dichlozid 1 Tab.(Hydrochlorothiazide 12.5 mg) would be administered orally once” NCT03032315 ↗
Known as	Dichlozid Tab	“Dichlozid Tab® (hydrochlorothiazide 25 mg)” NCT00496834 ↗
Known as	H12.5	“50 mg losartan potassium (L50), 12.5 mg hydrochlorothiazide (H12.5), and 5 mg amlodipine besylate (A5)” NCT01302691 ↗
Known as	HCT	“The majority of patients with essential hypertension of moderate severity (WHO grade 2) require combination therapy. We aimed to investigate whether the single-pill combination...” PMID 21117946 ↗ Nov 2010 6 “Angiotensin-converting enzyme inhibitors combined with higher doses of hydrochlorothiazide (HCT), that is, 25 mg daily, have been recognized as an effective form of...” PMID 18463672 ↗ May 2008 “PURPOSE: To investigate the pharmacokinetic/pharmacodynamic (PK/PD) interaction between irbesartan (IRB) and hydrochlorothiazide (HCT) in normotensive subjects.” PMID 25545238 ↗ Feb 2015 “At visit 4, if the patients did not achieve BP goal, HCT 12.5 mg/day was added to Aliskiren/Amlodipine/HCT (300/10/12.5 mg/day) for 4 weeks.” NCT01070030 ↗ “single-pill combination of the direct renin inhibitor aliskiren and hydrochlorothiazide (HCT)” PMID 19203020 ↗ Dec 2008 “Hydrochlorothiazide (HCT)” NCT07593612 ↗ “Hydrochlorothiazide (HCT)” NCT00775814 ↗
Known as	HCT G.L	“hydrochlorothiazide (HCT G.L) 25mg” NCT06710600 ↗
Known as	HCTZ	“The general aim and clinical objective of this trial is to determine the effect of telmisartan 80 mg compared to losartan 50 mg + HCTZ (Hydrochlorothiazide) 12.5 mg on...” NCT02183701 ↗ 108 “OBJECTIVE: The aim of this study was to determine whether a triple combination of olmesartan medoxomil (OM), amlodipine besylate (AML), and hydrochlorothiazide (HCTZ) had a...” PMID 20678674 ↗ Jul 2010 “The purpose of this trial is to evaluate the safety and efficacy of combination therapy of aliskiren/hydrochlorothiazide (HCTZ) 150/25 mg and 300/25 mg compared with HCTZ 25 mg...” NCT00387517 ↗ “The authors examined effects of valsartan and hydrochlorothiazide (HCTZ) combined and alone on insulin sensitivity (using homeostasis model assessment-insulin resistance...” PMID 19120715 ↗ Dec 2008 “In patients with acute heart failure, the addition of hydrochlorothiazide (HCTZ) to furosemide increased the diuretic response in the CLOROTIC trial (Combining Loop with...” PMID 40590131 ↗ Jul 2025 “Then, losartan 50 mg for 4 weeks, then titrate to losartan 100 mg at Week 4, then titrate to losartan 100 mg + hydrochlorothiazide (HCTZ) 12.5 mg at Week 8, and finally titrate...” NCT00289887 ↗ “This 28- to 54-week, open-label, multicenter study evaluated the safety and efficacy of a triple combination, aliskiren with amlodipine and hydrochlorothiazide (HCTZ), in...” PMID 23205748 ↗ Aug 2012 “Olmesartan medoxomil was uptitrated to 40 mg/day (weeks 4-6), then olmesartan medoxomil/hydrochlorothiazide (HCTZ) 40/12.5 mg per day (weeks 7-9), and olmesartan medoxomil/HCTZ...” PMID 20653330 ↗ 2010 “The impact of an ARB, with or without hydrochlorothiazide (HCTZ), on glycaemic factors and the risk for developing diabetes in hypertensive patients with the metabolic syndrome...” PMID 20147971 ↗ Feb 2010 “An eight week study to compare the effect of a fixed dose combination of Telmisartan 40 mg plus hydrochlorothiazide (HCTZ) 12.5 mg to Telmisartan 40 mg alone on diastolic and...” NCT02177500 ↗ “Hydrochlorothiazide (HCTZ) ATC class: C03AA03 Form: Tablet Dose range: Phase 1: 25mg (2 x 12.5mg tablet) Phase 2: 50mg (4 x 12.5mg tablet) Maximum allowed dose: 50mg...” NCT02351973 ↗ “This study aimed to evaluate the long-term safety and efficacy of a triple combination therapy with 20 mg azilsartan (AZL), 5 mg amlodipine (AML) and 12.5 mg hydrochlorothiazide (HCTZ).” PMID 29235365 ↗ Dec 2017 “The antihypertensive efficacy and tolerability of losartan (LST) in fixed combination with hydrochlorothiazide (HCTZ) has not been compared to those of amlodipine monotherapy in Asians.” PMID 19949604 ↗ Apr 2009 “the blood pressure (BP)-lowering efficacy and safety of an olmesartan medoxomil (OM)/hydrochlorothiazide (HCTZ)-based titration regimen in patients aged ≥65 years with hypertension.” PMID 21639407 ↗ Jun 2011 “This non-randomized study investigated whether valsartan 160 mg/hydrochlorothiazide 25 mg (Val 160/HCTZ 25) in fixed dose combination could provide additional blood pressure control” PMID 17922981 ↗ Nov 2007 “Thiazide doses equivalent to 1 to 2 mg/kg/d of hydrochlorothiazide (HCTZ) have been proposed to correct hypercalciuria and prevent kidney failure in patients with Dent disease.” PMID 18976849 ↗ Oct 2008 “comparing valsartan monotherapy with valsartan/hydrochlorothiazide (HCTZ) combination therapy as initial treatment for high-risk patients with stage 2 hypertension” PMID 18498915 ↗ Apr 2008 “Optional add-on of hydrochlorothiazide (HCTZ) (12.5-25 mg) was allowed (as applicable per local country regulations) for adequate blood pressure control.” NCT01256411 ↗ “We performed 12-hour urine collections in 7 patients taking 25 mg of chlorthalidone (CTD) and 10 patients taking 25 mg of hydrochlorothiazide (HCTZ).” PMID 40194294 ↗ Apr 2025 “Study to Evaluate the Efficacy and Safety of Aliskiren Hydrochlorothiazide (HCTZ) vs Ramipril in Obese patients (BMI ≥ 30) with Stage 2 Hypertension” NCT00772577 ↗ “Both Olmesartan (OLM)/Amlodipine (AML) combination and Hydrochlorothiazide (HCTZ) have proven to be efficacious and safe in lowering blood pressure” NCT00902538 ↗ “This study investigated potential pharmacokinetic drug-drug interactions between empagliflozin and hydrochlorothiazide (HCTZ) or torasemide (TOR).” PMID 25636696 ↗ Jan 2015 “olmesartan medoxomil (OM) /hydrochlorothiazide (HCTZ) tablets 40mg/25mg + 20mg/12.5mg matching placebo tablet once daily for 8 weeks” NCT00430508 ↗ “Optional addition of Hydrochlorothiazide (HCTZ)of 12.5 mg with increase to 25 mg was allowed for patients not adequately controlled.” NCT00402103 ↗ “Antihypertensive efficacy and safety of losartan/hydrochlorothiazide (HCTZ) combinations have not been adequately studied in Asians.” PMID 19390542 ↗ Apr 2009 “losartan potassium 50 mg/12.5 Hydrochlorothiazide (HCTZ) titrated as needed to losartan potassium 100 mg/25 mg Hydrochlorothiazide” NCT00546754 ↗ “Patients will be given Losartan LS (50 mg per day) and Hydrochlorothiazide (HCTZ) 12.5 mg per day as a combination therapy.” NCT06491940 ↗ “Hydrochlorothiazide (HCTZ) 12.5 mg for week 1; Hydrochlorothiazide (HCTZ) 25 mg (with or without amlodipine)for 7 weeks” NCT00760266 ↗ “Benazepril hydrochloride (HCl)/hydrochlorothiazide (HCTZ) 20/12.5 mg capsules for oral administration once daily.” NCT00170950 ↗ “This study will give the patients nebivolol or hydrochlorothiazide (HCTZ) for 6 weeks after 2 weeks of placebo.” NCT02710071 ↗ “hydrochlorothiazide (HCTZ) is a drug indicated for the treatment of patients with mild to moderate hypertension” NCT01294631 ↗ “Coated, Oral tablet containing Olmesartan medoxomil(OM)-Hydrochlorothiazide(HCTZ) 20-12.5mg, given once a day.” NCT01838850 ↗ “olmesartan medoxomil plus hydrochlorothiazide (HCTZ) in patients with hypertension and type 2 diabetes” PMID 21777013 ↗ Sep 2011 “the investigator will have the option, according to his clinical criteria, to add 12.5 mg of HCTZ QD” NCT03294070 ↗ “valsartan/hydrochlorothiazide 160/25 (Fixed Dose Combination of Valsartan 160 mg Plus HCTZ 25 mg)” NCT00171015 ↗ “hydrochlorothiazide (HCTZ) + potassium, 12.5 mg/10 milliequivalents (mEq) capsule daily” NCT00865124 ↗ “Hydrochlorothiazide (HCTZ) 12.5 mg tablets taken once a day during the Extension Phase.” NCT00523744 ↗ “Olmesartanmedoxomil (OM) /Hydrochlorothiazide (HCTZ)40/12.5 mg tablets once daily” NCT00441350 ↗ “amlodipine (AML)/olmesartan medoxomil (OM)±hydrochlorothiazide (HCTZ) algorithm” PMID 23254596 ↗ Dec 2012 “telmisartan 80 mg + hydrochlorothiazide (HCTZ) 12.5 mg fixed dose combination” NCT01911780 ↗ “one 12.5 mg hydrochlorothiazide (HCTZ) tablet daily, orally, for 12 weeks.” NCT00806585 ↗ “60 mg FMS + 12.5 mg hydrochlorothiazide (HCTZ) once a day during 4 weeks.” NCT02466490 ↗ “then crossed over to hydrochlorothiazide (HCTZ) once daily for 2 weeks” NCT02412761 ↗ “hydrochlorothiazide (HCTZ) 25mg OD, increased to 50 mg OD at 3 weeks.” NCT00834600 ↗ “combination valsartan/hydrochlorothiazide (HCTZ) vs. amlodipine/HCTZ” PMID 21974760 ↗ Jul 2011 “Chlorthalidone (CTD) may be superior to hydrochlorothiazide (HCTZ)” PMID 36067089 ↗ Sep 2022 “Losartan 50 mg / Hydrochlorothiazide (HCTZ) 12.5 mg Combination” NCT01431508 ↗ “Telmisartan / Hydrochlorothiazide (HCTZ) Fixed Dose Combination” NCT02187523 ↗ “500 mg BID + hydrochlorothiazide (HCTZ) 25 mg once daily \[QD\]” NCT03198793 ↗ “Hydrochlorothiazide (HCTZ) is a common anti-hypertensive drug.” PMID 38828023 ↗ May 2024 “olmesartan medoxomil (OM)+ hydrochlorothiazide (HCTZ) tablets” NCT00430950 ↗ “hydrochlorothiazide (HCTZ; n=104) or azelnidipine (n=103)” PMID 21241987 ↗ Dec 2010 “Valsartan and hydrochlorothiazide (HCTZ) - monotherapy” NCT00902304 ↗ “Verapamil SR/Trandolapril/Hydrochlorothiazide (HCTZ)” NCT00133692 ↗ “Aliskiren/Amlodipine and Hydrochlorothiazide (HCTZ)” NCT00942994 ↗ “losartan 50 mg/hydrochlorothiazide (HCTZ) 12.5 mg” NCT00447603 ↗ “the thiazide diuretic hydrochlorothiazide (HCTZ)” PMID 32039215 ↗ Jan 2020 “combination valsartan/hydrochlorothiazide (HCTZ)” PMID 20010618 ↗ Dec 2009 “Aliskiren/hydrochlorothiazide (HCTZ) (300/25 mg)” NCT00705575 ↗ “telmisartan 80 mg and HCTZ (Hydrochlorothiazide)” NCT02177422 ↗ “hydrochlorothiazide (HCTZ) 25 mg for 9 days” NCT01198249 ↗ “Hydrochlorothiazide (HCTZ) 25 milligrams.” NCT07469722 ↗ “Hydrochlorothiazide (HCTZ) 25 milligrams.” NCT07687160 ↗ “multiple-dose hydrochlorothiazide (HCTZ)” NCT03387657 ↗ “Hydrochlorothiazide (HCTZ) 12.5-25 mg” NCT00386607 ↗ “Valsartan/hydrochlorothiazide (HCTZ)” NCT00548067 ↗ “hydrochlorothiazide (HCTZ) 25 mg/day” PMID 28509725 ↗ Oct 2017 “hydrochlorothiazide (HCTZ) 12.5 mg” NCT00240474 ↗ “hydrochlorothiazide (HCTZ) 12.5 mg” NCT02177435 ↗ “hydrochlorothiazide (HCTZ) 6.25 mg” NCT00153049 ↗ “hydrochlorothiazide (HCTZ) 12.5 mg” NCT01975246 ↗ “Hydrochlorothiazide (HCTZ))” NCT00396656 ↗ “Losartan 100mg/ HCTZ 12.5mg” NCT01828359 ↗ “Hydrochlorothiazide (HCTZ)” NCT02183675 ↗ “Hydrochlorothiazide (HCTZ)” NCT00765674 ↗ “Hydrochlorothiazide (HCTZ)” NCT01302899 ↗ “hydrochlorothiazide (HCTZ)” PMID 18593517 ↗ Jun 2008 “Hydrochlorothiazide (HCTZ)” NCT06681116 ↗ “Hydrochlorothiazide (HCTZ)” NCT01370655 ↗ “hydrochlorothiazide (HCTZ)” NCT00496834 ↗ “Hydrochlorothiazide (HCTZ)” NCT02072330 ↗ “Hydrochlorothiazide (HCTZ)” NCT01113047 ↗ “Hydrochlorothiazide (HCTZ)” NCT02185417 ↗ “Hydrochlorothiazide (HCTZ)” NCT02276378 ↗ “Hydrochlorothiazide (HCTZ)” NCT01259297 ↗ “Hydrochlorothiazide (HCTZ)” NCT00671424 ↗ “Hydrochlorothiazide (HCTZ)” NCT00787605 ↗ “HCTZ-hydrochlorothiazide” NCT00574834 ↗ “HCTZ 12.5 mg capsule.” NCT00698646 ↗ “HCTZ” NCT00621153 ↗ NCT00095394 ↗ NCT00144222 ↗ NCT00171574 ↗ NCT00095550 ↗ NCT01804777 ↗ NCT00171600 ↗ NCT01056731 ↗ NCT00744237 ↗ NCT03249285 ↗ NCT01271374 ↗ NCT00160160 ↗ NCT00326768 ↗ NCT00931710 ↗ NCT02094924 ↗ NCT02262780 ↗ NCT03115853 ↗ NCT02262572 ↗ NCT00327587 ↗ NCT02176512 ↗
Known as	HTC	“administration of hydrochlorothiazide (HTC) once daily for 4 days (10 patients)” NCT01276288 ↗
Known as	Hydrochlorothiazid	ClinicalTrials.gov intervention name — accepted as the source's own label NCT01879527 ↗
Known as	hydrochlorothiazide 25 milligrams	“hydrochlorothiazide 25 milligrams” NCT07008365 ↗
Known as	Hydrochlorthiazide	“Hydrochlorthiazide® (Hydrochlorothiazide)” NCT02774460 ↗
Known as	Hyzaar	ClinicalTrials.gov intervention name — accepted as the source's own label NCT01620788 ↗
Known as	Thiazide	ClinicalTrials.gov intervention name — accepted as the source's own label NCT00232882 ↗
Action	Inhibit	“Na-Cl co-transporter activity is inhibited by thiazides.” PMID 20555294 ↗ Aug 2010
Route	Oral	“Tablets, Oral” NCT00095394 ↗